Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Phase: PHASE3
Conditions: Atypical Hemolytic Uremic Syndrome (aHUS)
Sponsor: Alexion Pharmaceuticals, Inc.

 
Single Arm Study of ALXN1210 in Complement Inhibitor 
Treatment-naïve Adult and Adolescent Patients With 
Atypical Hemolytic Uremic Syndrome (aHUS) 
 
 
 
Unique Protocol ID:  
ALXN1210-aHUS-311  
NCT Number:  
NCT02949128 
EudraCT Number:  
2016-002027-29 
Date of Protocol:  
07 May 2019 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 1 of 86 
CONFIDENTIAL 
1. 
TITLE PAGE 
PROTOCOL ALXN1210-aHUS-311 
SINGLE ARM STUDY OF ALXN1210 IN COMPLEMENT INHIBITOR 
TREATMENT-NAÏVE ADULT AND ADOLESCENT PATIENTS WITH 
ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) 
 
Sponsor: 
Alexion Pharmaceuticals, Inc. (Alexion) 
100 College Street 
New Haven, CT 06510 USA 
 
Sponsor Contact: 
 
Alexion Pharmaceuticals, Inc.  
121 Seaport Blvd, 7th Floor 
Boston, MA 02210 USA 
Telephone: 
 
Email: 
 
 
Medical Monitor: 
 
 
Alexion Pharmaceuticals, Inc. 
121 Seaport Blvd, 7th Floor 
Boston, MA 02210 USA 
Telephone: 
 
Email: 
 
IND Number: 
128367 
EudraCT Number: 
2016‐002027‐29 
 
 
Date of Initial Protocol: 
09 Aug 2016 
Amendment 1: 
28 Sep 2016 
Amendment 2 (Global): 
23 Jan 2017 
Amendment 3 (Global): 
19 Jul 2017 
Amendment 4 (Global): 
07 May 2019 
 
 
 
PPD
PPD
PPD
PPD
PPD
PPD

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 2 of 86 
CONFIDENTIAL 
 
This protocol contains confidential information and is provided for exclusive use of 
Investigators. This information may only be disclosed to those persons involved in this study 
who have a need to know with the obligation not to further disseminate this information. This 
information may not be disclosed to other individuals unless such disclosure is required by 
country, federal, or state law or regulations subject to the foregoing. These restrictions on 
disclosure will apply equally to all future oral or written information supplied to you by Alexion 
which is designated as “privileged” or “confidential.” 

PPD

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 4 of 86 
CONFIDENTIAL 
INVESTIGATOR’S AGREEMENT 
 
I have received and read the Investigator’s Brochure for ALXN1210. I have read the 
ALXN1210-aHUS-311 study protocol and agree to conduct the study in accordance with this 
protocol, all applicable government regulations, the principles of the ICH E6 Guidelines for 
Good Clinical Practice, and the principles of the World Medical Association Declaration of 
Helsinki. I also agree to maintain the confidentiality of all information received or developed in 
connection with this protocol.  
 
 
 
 
 
____________________________________ 
Printed Name of Investigator 
 
_____________________________________ 
Signature of Investigator 
 
_______________ 
Date 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 5 of 86 
CONFIDENTIAL 
STUDY CONTACT INFORMATION 
 
Emergency Contact Information 
Study Role 
Name 
Address and Telephone Number 
Clinical Project Leader 
Alexion Pharmaceuticals, Inc.  
121 Seaport Blvd, 7th Floor 
Boston, MA 02210 USA 
Telephone: 
 
Email: 
 
Medical Monitor 
Alexion Pharmaceuticals, Inc. 
121 Seaport Blvd, 7th Floor 
Boston, MA 02210 USA 
Telephone: 
  
Email: 
 
24-Hour Emergency Contact 
Phone Number 
 
 
 
 
 
PPD
PPD
PPD
PPD
PPD
PPD

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 6 of 86 
CONFIDENTIAL 
2. 
SYNOPSIS 
Name of Sponsor/Company: Alexion Pharmaceuticals, Inc. 
Name of Investigational Product: ALXN1210 
Name of Active Ingredient: ALXN1210 
Title of Study: Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent 
Patients with Atypical Hemolytic Uremic Syndrome (aHUS)  
Protocol Number: ALXN1210-aHUS-311 
EudraCT Number: 2016-002027-29 
Study Centers: Approximately 200 investigative sites globally. 
Length of Study:  
Estimated date first patient treated: Nov 2016 
Actual first patient treated: Mar 2017 
Estimated date last patient completed (last patient last visit): 
May 2023 
Phase of Development: 3 
 
Primary Objective:  
The primary objective of the study is to assess the efficacy of ALXN1210 in complement inhibitor treatment-naïve 
adolescent and adult patients with aHUS to inhibit complement-mediated thrombotic microangiopathy (TMA) as 
characterized by thrombocytopenia, hemolysis, and renal impairment. 
  
Secondary Objectives: 
The secondary objectives of the study are to assess the following: 
1. To characterize the safety and tolerability of ALXN1210 in this patient population 
2. To evaluate the efficacy of ALXN1210 by the following additional measures: 
a. 
Dialysis requirement status 
b. Time to Complete TMA Response 
c. 
Complete TMA Response status over time 
d. Observed value and change from baseline in estimated glomerular filtration rate (eGFR) 
e. 
Chronic kidney disease (CKD) stage, as evaluated by eGFR at select target days and classified as 
improved, stable (no change), or worsened compared to baseline 
f. 
Observed value and change from baseline in hematologic parameters (platelets, lactate 
dehydrogenase [LDH], hemoglobin) 
g. Increase in hemoglobin of ≥ 20 g/L from baseline, observed at 2 separate assessments obtained at 
least 4 weeks (28 days) apart, and any measurement in between 
h. Change from baseline in quality of life (QoL), as measured by EuroQol 5 dimensions 3 level (EQ-
5D-3L; all patients), Functional Assessment of Chronic Therapy (FACIT) Fatigue version 4 (patients 
≥ 18 years of age), and Pediatric FACIT Fatigue (patients < 18 years of age) questionnaires 
i. 
TMA parameters in patients who discontinue treatment but remain in the study 
3. To characterize the pharmacokinetics (PK)/pharmacodynamics (PD) of ALXN1210 by the following 
measures: 
a. 
Changes in serum ALXN1210 concentration over time  
b. Changes in free complement component 5 (C5) concentrations over time 
c. 
Changes in free C5 and ALXN1210 concentration in patients who discontinue treatment but remain 
in the study 
4. To evaluate the long-term safety and efficacy of ALXN1210 
Study Design and Methodology: This is a Phase 3, single arm, multicenter study to evaluate the safety and 
efficacy of ALXN1210 administered by intravenous (IV) infusion to adolescent (12 to < 18 years of age) and adult 
(≥ 18 years of age) patients with aHUS. All patients must be naïve to complement inhibitor treatment and include 
at least 6 and up to 10 adolescent (12 to < 18 years of age at Screening) patients and at least 10 and up to 25 
patients with prior kidney transplants. A minimum of 30 patients who meet all laboratory criteria for TMA (platelet 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 7 of 86 
CONFIDENTIAL 
count of < 150,000 per microliter, LDH ≥ 1.5 × upper limit of normal (ULN), hemoglobin ≤ lower limit of normal 
(LLN), and serum creatinine level ≥ ULN) as determined by the central laboratory at Day 1, will be enrolled. The 
study consists of an up to 7-day Screening Period, a 26-week Initial Evaluation Period and an Extension Period 
until the product is registered or approved (in accordance with country-specific regulations) or for up to 4.5 years, 
whichever occurs first. Patients will receive a weight-based loading dose of ALXN1210 IV 
(≥ 40 to < 60 kg = 2400 mg; ≥ 60 to < 100 kg = 2700 mg; ≥ 100 kg = 3000 mg) on Day 1, followed by weight-
based maintenance doses of ALXN1210 IV (≥ 40 to < 60 kg = 3000 mg; ≥ 60 to < 100 kg = 3300 mg; 
≥ 100 kg = 3600 mg) on Day 15 and once every 8 weeks (q8w) thereafter for a total of 26 weeks of treatment in the 
Initial Evaluation Period followed by maintenance doses q8w in the Extension Period. The end of trial is defined as 
the last patient’s last visit. Weight-based dosing is based on the patient’s body weight recorded at the last visit or 
more recently. 
 
Number of Patients (planned): Approximately 55 patients are planned for enrollment.  
Diagnosis and Main Criteria for Inclusion and Exclusion:  
Patients must meet all inclusion and no exclusion criteria. Patients who fail any of the eligibility criteria may be 
rescreened based on discussion and agreement between the Investigator and the Medical Monitor. Patients may be 
rescreened a maximum of 2 times. Evaluation of Inclusion Criteria 2a and 2b may be based on local laboratory 
results within 28 days prior to the start of the Screening Period or laboratory results obtained during the Screening 
Period from a local or central laboratory. If a local laboratory is used to define eligibility, additional samples will 
be collected during the Screening Period for LDH, platelet count, hemoglobin and serum creatinine and tested at 
the central laboratory.  If patients are found to not meet the eligibility criteria for serum creatinine (Inclusion 
Criterion 2c) based on central laboratory results, they must not be enrolled into the study; if the subject has 
received the first dose of ALXN1210 the patient must be withdrawn from the study, and may be replaced. All 
analyses in this study will be based on results from the central laboratory. A central laboratory result for Inclusion 
Criterion 2c may not be available prior to first dose; results received after the first dose indicating that eligibility is 
not satisfied could lead to discontinuation and replacement of the patient. 
 
The study will enroll at least 6 and up to 10 adolescent (12 to < 18 years of age at Screening) patients and at least 
10 and up to 25 patients with prior kidney transplants. A minimum of 30 patients who meet all laboratory criteria 
for TMA (platelet count of < 150,000 per microliter, LDH ≥ 1.5 × upper limit of normal (ULN), hemoglobin ≤ 
lower limit of normal (LLN), and serum creatinine level ≥ ULN) as determined by the central laboratory at Day 1, 
will be enrolled. 
 
Inclusion Criteria:  
1. Male or female patients ≥ 12 years of age and weighing ≥ 40 kg at the time of consent. 
2. Evidence of TMA, including thrombocytopenia, evidence of hemolysis, and kidney injury, based on the 
following laboratory findings: 
a. 
Platelet count < 150,000 per microliter (µL) during the Screening Period or within 28 days prior to 
the start of the Screening Period, and 
b. LDH ≥ 1.5 × upper limit of normal (ULN) during the Screening Period or within 28 days prior to the 
start of the Screening Period, and hemoglobin ≤ lower limit of normal (LLN) for age and gender 
during the Screening Period or within 28 days prior to the start of the Screening Period, and 
c. 
Serum creatinine level ≥ ULN during the Screening Period in adults (≥18 years of age), or ≥ 97.5th 
percentile for age at Screening in adolescents (≥ 12 to < 18 years of age) (patients who require 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 8 of 86 
CONFIDENTIAL 
dialysis for acute kidney injury are also eligible). 
3. Among patients with a kidney transplant: 
a. 
Known history of aHUS prior to current kidney transplant, or 
b. No known history of aHUS, and persistent evidence of TMA at least 4 days after modifying the 
immunosuppressive regimen (eg, suspending or reducing the dose) of calcineurin inhibitor ([CNI]; 
eg, cyclosporine, tacrolimus) or mammalian target of rapamycin inhibitor ([mTORi]; eg, sirolimus, 
everolimus). 
4. Among patients with onset of TMA postpartum, persistent evidence of TMA for > 3 days after the day of 
childbirth. 
5. To reduce the risk of meningococcal infection (Neisseria meningitidis), all patients must be vaccinated 
against meningococcal infections within 3 years prior to, or at the time of, initiating study drug. Patients 
who receive a meningococcal vaccine less than 2 weeks before initiating ALXN1210 treatment must 
receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Patients who 
have not been vaccinated prior to initiating ALXN1210 treatment should receive prophylactic antibiotics 
prior to and for at least 2 weeks after meningococcal vaccination. 
6. Patients < 18 years of age must have been vaccinated against Haemophilus influenzae type b (Hib) and 
Streptococcus pneumoniae according to national and local vaccination schedule guidelines. 
7. Female patients of childbearing potential and male patients with female partners of childbearing potential 
must follow protocol-specified guidance for avoiding pregnancy while on treatment and for 8 months after 
last dose of study drug. 
8. Willing and able to give written informed consent and comply with the study visit schedule. For patients 
< 18 years of age, patient's legal guardian must be willing and able to give written informed consent and 
the patient must be willing to give written informed assent (if applicable as determined by the central or 
local Institutional Review Board [IRB]/Institutional (or Independent) Ethics Committee [IEC]).  
 
Exclusion Criteria: 
1. Known familial or acquired ‘a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 
member 13’ (ADAMTS13) deficiency (activity < 5%). Eligibility may be defined using results from tests 
carried out as standard of care for the treatment of the current TMA prior to a patient giving informed 
consent. In these cases informed consent will be provided prior to collecting the data for the trial. 
2. Known Shiga toxin-related hemolytic uremic syndrome (ST-HUS) as demonstrated by a positive test for 
Shiga toxin or culture of Shiga toxin producing bacteria. Eligibility may be defined using results from 
tests carried out as standard of care for the treatment of the current TMA prior to a patient giving 
informed consent. In these cases informed consent will be provided prior to collecting the data for the 
trial. 
3. Positive direct Coombs test. Eligibility may be defined using results from tests carried out as standard of 
care for the treatment of the current TMA prior to a patient giving informed consent. In these cases 
informed consent will be provided prior to collecting the data for the trial. 
4. Known Human Immunodeficiency Virus (HIV) infection. 
5. Unresolved meningococcal disease. 
6. Patients with a confirmed diagnosis of ongoing sepsis defined as positive blood cultures within 7 days 
prior to the start of Screening and untreated with antibiotics. 
7. Presence or suspicion of active and untreated systemic bacterial infection that, in the opinion of the 
Investigator, confounds an accurate diagnosis of aHUS or impedes the ability to manage the aHUS 
disease. 
8. Pregnancy or breastfeeding. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 9 of 86 
CONFIDENTIAL 
9. Heart, lung, small bowel, pancreas, or liver transplant. 
10. Among patients with a kidney transplant, acute kidney dysfunction within 4 weeks of transplant consistent 
with the diagnosis of acute antibody-mediated rejection (AMR) according to Banff 2013 criteria. 
11. Among patients without a kidney transplant, history of kidney disease other than aHUS, such as: 
a. 
Known kidney biopsy finding suggestive of underlying disease other than aHUS 
b. Known kidney ultrasound finding consistent with an alternative diagnosis to aHUS (eg small kidneys 
for age) 
c. 
Known family history and/or genetic diagnosis of noncomplement mediated genetic renal disease (eg, 
focal segmental glomerulosclerosis) 
12. Identified drug exposure-related HUS. 
13. Receiving plasma exchange/plasma infusion (PE/PI), for 28 days or longer, prior to the start of Screening 
for the current TMA.  
14. History of malignancy within 5 years of Screening with the exception of a nonmelanoma skin cancer or 
carcinoma in situ of the cervix that has been treated with no evidence of recurrence. 
15. Bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) within the last 6 months prior 
to the start of Screening. 
16. HUS related to known genetic defects of cobalamin C metabolism. 
17. Known systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or antiphospholipid 
antibody positivity or syndrome. 
18. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for end-stage kidney 
disease [ESKD]). 
19. Patients receiving chronic intravenous immunoglobulin (IVIg) within 8 weeks prior to the start of 
Screening, unless for unrelated medical condition (eg, hypogammaglobinemia); or chronic rituximab 
therapy within 12 weeks prior to the start of Screening. 
20. Patients receiving other immunosuppressive therapies such as steroids, mTORi (eg, sirolimus, 
everolimus), CNI (eg, cyclosporine or tacrolimus) are excluded unless:  
a. 
part of an established post-transplant antirejection regimen, or  
b. patient has confirmed anti-complement factor antibodies requiring immunosuppressive therapy, or 
c. 
steroids are being used for a condition other than aHUS (eg, asthma). 
21. Participation in another interventional treatment study or use of any experimental therapy within 30 days 
before initiation of study drug on Day 1 in this study or within 5 half-lives of that investigational product, 
whichever is greater. 
22. Prior use of eculizumab or other complement inhibitors 
23. Hypersensitivity to any ingredient contained in the study drug, including hypersensitivity to murine 
proteins.  
24. Any medical or psychological condition that, in the opinion of the Investigator or Sponsor, could increase 
the risk to the patient by participating in the study or confound the outcome of the study. 
25. Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to the start of 
Screening. 
26. Use of tranexamic acid within 7 days prior to Screening is prohibited. 
Investigational Product, Dosage, and Mode of Administration:  
ALXN1210 loading dose on Day 1 and maintenance doses on Day 15 and q8w thereafter, administered by IV 
infusion. Dosages are based on the patient’s body weight, as shown in the table below:  
Body Weight 
Loading Dose (Day 1) 
Maintenance Doses (Days 15, 71, and 127) 
≥ 40 to < 60 kg 
2400 mg 
3000 mg 
≥ 60 to < 100 kg 
2700 mg 
3300 mg 
≥ 100 kg 
3000 mg 
3600 mg 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 10 of 86 
CONFIDENTIAL 
Planned Duration of Treatment: 26-week Initial Evaluation Period followed by an Extension Period until the 
product is registered or approved (in accordance with country-specific regulations) or for up to 4.5 years, 
whichever occurs first.  
Reference Therapy, Dosage, and Mode of Administration:  
Not applicable 
Endpoints:  
Efficacy Assessments  
Primary:  
Complete TMA Response during the 26-week Initial Evaluation Period, as evidenced by normalization of 
hematological parameters (platelet count and LDH) and ≥ 25% improvement in serum creatinine from 
baseline. Patients must meet all Complete TMA Response criteria at 2 separate assessments obtained at 
least 4 weeks (28 days) apart, and any measurement in between.  
Secondary: 
1. Dialysis requirement status 
2. Time to Complete TMA Response 
3. Complete TMA Response status over time 
4. Observed value and change from baseline in estimated glomerular filtration rate (eGFR) 
5. Chronic kidney disease (CKD) stage, as evaluated by eGFR at select target days and classified as 
improved, stable (no change), or worsened compared to baseline 
6. Observed value and change from baseline in hematologic parameters (platelets, LDH, hemoglobin) 
7. Increase in hemoglobin of ≥ 20 g/L from baseline, observed at 2 separate assessments obtained at least 4 
weeks (28 days) apart, and any measurement in between 
8. Change from baseline in quality of life (QoL), as measured by EuroQol 5 dimensions 3 level (EQ-5D-3L; 
all patients), Functional Assessment of Chronic Therapy (FACIT) Fatigue version 4 (patients ≥ 18 years 
of age), and Pediatric FACIT Fatigue (patients < 18 years of age) questionnaires 
9. TMA parameters in patients who discontinue treatment but remain in the study 
 
Pharmacokinetics/Pharmacodynamics  
1. Changes in serum ALXN1210 concentration over time  
2. Changes in free C5 concentrations over time 
3. Changes in free C5 and ALXN1210 concentration in patients who discontinue treatment but remain in the 
study 
 
Exploratory 
Biomarkers and APC Activity: 
Exploratory biomarkers of PD effect may include, but are not limited to, change from baseline in levels of markers 
of complement dysregulation (eg, Factor Ba), vascular inflammation (eg, soluble tumor necrosis factor receptor 1 
[sTNFR1]), endothelial activation/damage (eg, soluble vascular adhesion molecule 1 [sVCAM-1], 
thrombomodulin), coagulation (eg, D-dimer), and renal injury (eg, cystatin C). Additional assessments may include 
measurements of ALXN1210 excretion in urine, chicken red blood cell (cRBC) hemolysis, total C5, autoantibodies 
to complement proteins (eg, anti-factor H) and Alternative Pathway of Complement (APC) activity (eg, Modified 
Ham’s test, complement deposition assay). 
Genetics: 
Exploratory genetics may be performed to investigate genetic variants in genes known to be associated with aHUS, 
as well as to identify novel genetic variants associated with aHUS, complement dysregulation, or metabolism or 
efficacy of ALXN1210. Patients (or legal guardians) may decline from providing a sample for exploratory genetics 
and still participate in the study. 
 
Additional Signs or Symptoms of aHUS and Resource Utilization: 
Resource utilization will be assessed using the Resource Utilization Patient Questionnaire and additional signs or 
symptoms of aHUS will be assessed using the Patient-reported aHUS Symptoms Questionnaire.  

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 11 of 86 
CONFIDENTIAL 
The Investigator will evaluate extra-renal signs or symptoms of aHUS using a composite of clinical laboratory 
measurements, vital signs, and an organ system review. 
 
Safety  
The long-term safety and tolerability of ALXN1210 will be evaluated by physical examinations, vital signs, 
electrocardiograms (ECG), laboratory assessments, and incidence of adverse events (AEs) and serious adverse 
events (SAEs). The proportion of patients who develop antidrug antibodies (ADA) will also be assessed. 
Sample Size: 
Approximately 55 patients will be enrolled in this study in order to yield at least 50 evaluable patients by Day 183. 
This sample size is deemed appropriate to provide complete safety information and the necessary precision level 
for the planned estimation. Assuming a proportion of Complete TMA response of 65%, 50 patients would yield a 
95% confidence interval (CI) for the proportion of response with a half-width of approximately 15%. 
The sample size was increased to 55 patients to account for a potential 10% drop-out rate, thus yielding a total 
planned sample size of 55 patients.  
Statistical methods:  
General: All data collected will be presented using summary tables, figures, and data listings. All analyses will be 
performed using SAS® release, version 9.4 or higher (SAS Institute Inc., Cary, NC, USA) or other validated 
statistical software. Continuous variables will be summarized using descriptive statistics, including number of 
observations and mean, standard deviation (SD), median, minimum, and maximum values. Categorical variables 
will be summarized by frequency counts and percentage of patients. 
 
An interim clinical study report (CSR) will be prepared at the end of the 26-week Initial Evaluation Period, which 
will include efficacy, safety, and PK/PD analyses. A final CSR to summarize long-term efficacy, safety, and 
PK/PD will be produced at study completion. Available exploratory data will be summarized after study 
completion but may not be included in the CSR. All data collected will be presented using summary tables, figures, 
and data listings. 
 
Efficacy:  
Efficacy analyses will be performed on the Full Analysis Set (FAS). The analysis of the FAS will be the primary 
analysis.  
The FAS will be based on a modified intent to treat (mITT) approach where patients that were enrolled and treated 
based on verification of inclusion and exclusion criteria through local laboratory results and the assumption that all 
inclusion and exclusion criteria were satisfied will be excluded from the FAS if it is later shown that certain of the 
inclusion and exclusion criteria were in fact not satisfied once all Screening laboratory results are available. Based 
on the above, the FAS will include all patients who receive at least 1 dose of ALXN1210, have at least 1 
postbaseline efficacy assessment, and meet all of the following criteria:  
• 
Patients who satisfy Inclusion Criterion number 2c  
• 
Patients who satisfy Exclusion Criterion number 1 
• 
Patients who satisfy Exclusion Criterion number 2 
 
The FAS will be determined prior to database lock and prior to the database snapshot for the analysis performed at 
the end of the 26-week Initial Evaluation Period. 
 
Primary efficacy: 
The primary efficacy endpoint is Complete TMA Response during the 26-week Initial Evaluation Period. The 
primary analysis will consist in estimating the proportion of complete TMA responders among ALXN1210 treated 
patients. This will be performed by calculating the point estimate and a 95% CI for the proportion of complete 
TMA responders in ALXN1210 treated patients. The CI will be based on the asymptotic Gaussian approximation 
method with a continuity correction. 
 
Secondary efficacy: 
For the secondary efficacy endpoint of time to Complete TMA Response, a Kaplan-Meier cumulative distribution 
curve will be generated along with a 2-sided 95% CI. The corresponding summary table will present the 
cumulative distribution function (CDF) estimate, the number of patients at risk, the number of patients responding, 
and the number of patients censored at each postbaseline time point. The table will also present first quartile, 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 12 of 86 
CONFIDENTIAL 
median, and third quartile, along with corresponding 2-sided 95% CI, of time to complete response. 
 
Complete TMA response will also be summarized over time by presenting the number and proportion of 
responders along with a 2-sided 95% CI for each postbaseline time point. A similar approach will be used to 
summarize the number and proportion of patients with an increase from baseline in hemoglobin ≥ 20 g/L, observed 
at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any measurement in between. 
 
Kidney function (dialysis requirement status, eGFR, CKD stage) as well as hematologic parameters (platelets, 
LDH, hemoglobin) will be summarized at baseline and each postbaseline time point. Descriptive statistics for 
continuous variables (eGFR, platelets, LDH, hemoglobin) will be used to summarize the observed value as well as 
the change from baseline. A mixed model for repeated measures (MMRM) with the fixed, categorical effect of 
visit and fixed, continuous effect of the specific test’s baseline value as covariates may be fit to test whether 
changes differ from zero at each time point. Dialysis requirement status and CKD stage will be summarized over 
time. Dialysis requirement status will be summarized among patients receiving dialysis within 5 days prior to 
ALXN1210 treatment initiation by presenting the number and proportion of those patients receiving and not 
receiving dialysis at each time point. A 2-sided 95% CI for the proportion receiving dialysis will be provided. CKD 
stage will be summarized over time by presenting the number and proportion of patients that improved (excluding 
those with Stage 1 at baseline as they cannot improve), worsened (excluding those with Stage 5 at baseline as they 
cannot worsen), and stayed the same compared to CKD stage at baseline. Stage 5 will be considered the worst 
category, while Stage 1 will be considered the best category. A 2-sided 95% CI for the proportion will be provided 
for each category.  
 
Quality of life will be evaluated using EQ-5D-3L (all patients), FACIT Fatigue version 4 (patients ≥ 18 years of 
age), and Pediatric FACIT Fatigue (patients < 18 years of age) questionnaires. These measures will be summarized 
at baseline and each postbaseline time point using descriptive statistics for continuous variables for the observed 
value as well as the change from baseline. A MMRM with the fixed, categorical effect of visit and fixed, 
continuous effect of the specific test’s baseline value as covariates may be fit to test whether changes differ from 
zero at each time point. 
 
Safety: 
Safety analyses will be performed on the Safety Set defined as all patients who received at least 1 dose of 
ALXN1210. The incidence of treatment-emergent adverse events (TEAEs) and SAEs will be summarized by 
system organ class (SOC) and preferred term (PT) overall, by severity, and by relationship to treatment.  
 
Observed values and changes from baseline (last assessment prior to ALXN1210) in ECGs, vital signs, and 
laboratory assessments, as well as presence of ADA will be summarized. Shifts from baseline in laboratory 
assessments will be summarized for all study visits. 
 
Pharmacokinetics/Pharmacodynamics:  
Sparse PK and PD (free C5) samples will be collected over the course of the study. Individual serum concentration 
data for all patients who receive at least 1 infusion of ALXN1210 and who have evaluable PK data will be used to 
derive the PK parameters for ALXN1210. 
 
Graphs of mean serum concentration-time profiles will be constructed. Graphs of serum concentration-time 
profiles for individual patients may also be provided. Actual dose administration and sampling times will be used 
for all calculations. Descriptive statistics will be calculated for serum concentration data at each sampling time, as 
appropriate. Assessment of population-PK may be considered using data from this study or in combination with 
data from other studies. 
 
The PD effects of ALXN1210 administered IV will be evaluated by assessing the absolute values and changes and 
percentage changes from baseline in free C5 serum concentrations over time, as appropriate. Assessments of 
PK/PD relationships may be explored using data from this study or in combination with data from other studies.  
Pharmacodynamic analyses will be performed for all patients who receive at least 1 infusion of study drug and who 
have evaluable PD data. For PD parameters, summary tabulations of mean, SD, median, minimum, and maximum 
values will be presented for actual, change and percentage change from baseline. The relationship between changes 
in PD parameters, exploratory biomarkers, and the effects of treatment outcome may be evaluated. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 13 of 86 
CONFIDENTIAL 
 
Exploratory: 
Biomarkers and APC Activity: 
Exploratory analyses will evaluate changes from baseline in biomarkers which may include, but are not limited to, 
markers of complement dysregulation (eg, Factor Ba), vascular inflammation (eg, sTNFR1), endothelial 
activation/damage (eg, sVCAM-1, thrombomodulin) coagulation (eg, D-dimer), and renal injury (eg, cystatin C). 
Additional analysis may include evaluation of ALXN1210 excretion in urine, cRBC hemolysis, total C5, 
autoantibodies to complement proteins (eg, anti-factor H) and APC activation (eg, Modified Ham’s test, 
complement deposition assays). 
 
Genetics:  
Exploratory genetics may be performed to investigate genetic variants in genes known to be associated with aHUS, 
as well as to identify novel genetic variants associated with aHUS, complement dysregulation, or metabolism or 
efficacy of ALXN1210. Patients (or legal guardians) may decline from providing a sample for exploratory genetics 
and still participate in the study. 
 
Additional Signs or Symptoms of aHUS and Resource Utilization: 
Resource utilization will be assessed using the Resource Utilization Patient Questionnaire (caregiver-reported for 
all patients) and additional signs or symptoms of aHUS will be assessed using the Patient-reported aHUS 
Symptoms Questionnaire (patient-reported for patients ≥ 12 years of age; caregiver-reported for patients < 12 years 
of age). Resource Utilization Questionnaire data and Patient-reported aHUS Symptoms Questionnaire data will be 
summarized at baseline and each postbaseline assessment using discrete data summary statistics.  
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 14 of 86 
CONFIDENTIAL 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF 
FIGURES  
TABLE OF CONTENTS 
1. 
TITLE PAGE ................................................................................................................1 
SPONSOR SIGNATURE PAGE ....................................................................................................3 
INVESTIGATOR’S AGREEMENT ...............................................................................................4 
STUDY CONTACT INFORMATION ...........................................................................................5 
2. 
SYNOPSIS ...................................................................................................................6 
3. 
TABLE OF CONTENTS, LIST OF TABLES, AND LIST OF FIGURES ...............14 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS .............................20 
5. 
INTRODUCTION ......................................................................................................22 
5.1. 
Benefits and Risks Assessment ..................................................................................23 
5.1.1. 
Potential Benefits ........................................................................................................23 
5.1.2. 
Identified and Potential Risks .....................................................................................23 
5.1.2.1. 
Infections (N. Meningitidis and Other Encapsulated Organisms) ..............................23 
5.1.2.2. 
Immunogenicity ..........................................................................................................23 
5.1.2.3. 
Pregnancy Exposure ...................................................................................................24 
6. 
STUDY OBJECTIVES AND ENDPOINTS ..............................................................25 
6.1. 
Study Objectives .........................................................................................................25 
6.1.1. 
Primary Objective .......................................................................................................25 
6.1.2. 
Secondary Objectives .................................................................................................25 
6.2. 
Endpoints ....................................................................................................................26 
6.2.1. 
Primary Efficacy Endpoint .........................................................................................26 
6.2.2. 
Secondary Efficacy Endpoints ....................................................................................26 
6.2.3. 
Pharmacokinetic and Pharmacodynamic Endpoints ...................................................26 
6.2.4. 
Safety Endpoints .........................................................................................................26 
6.2.5. 
Exploratory Endpoints ................................................................................................27 
6.2.5.1. 
Biomarkers and APC Activity Endpoints ...................................................................27 
6.2.5.2. 
Genetics Endpoints .....................................................................................................27 
6.2.5.3. 
Additional Signs or Symptoms of aHUS and Resource Utilization ...........................27 
7. 
INVESTIGATIONAL PLAN .....................................................................................28 
7.1. 
Summary of Study Design ..........................................................................................28 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 15 of 86 
CONFIDENTIAL 
7.2. 
Discussion of Design ..................................................................................................28 
7.3. 
Schedule of Assessments ............................................................................................29 
8. 
STUDY POPULATION .............................................................................................37 
8.1. 
Inclusion Criteria ........................................................................................................37 
8.2. 
Exclusion Criteria .......................................................................................................38 
8.3. 
Discontinuation ...........................................................................................................40 
8.3.1. 
Early Termination of Patients From the Study ...........................................................40 
8.3.2. 
Discontinuation of ALXN1210 Treatment and Continuation in the Study ................41 
8.3.2.1. 
Retreatment of Patients who Discontinue ALXN1210 Treatment .............................42 
8.3.3. 
Discontinuation of Study/Site Termination by Sponsor or Health Authority ............43 
8.3.4. 
Replacements ..............................................................................................................43 
8.3.5. 
End of Study Definition ..............................................................................................43 
9. 
STUDY TREATMENT ..............................................................................................44 
9.1. 
Materials and Supplies ................................................................................................44 
9.1.1. 
Description of Study Drugs ........................................................................................44 
9.1.2. 
Study Drug Packaging and Labeling ..........................................................................44 
9.1.3. 
Study Drug Storage .....................................................................................................44 
9.1.4. 
Study Drug Preparation and Infusion .........................................................................45 
9.1.5. 
Study Drug Handling and Disposal ............................................................................45 
9.2. 
Treatments Administered ............................................................................................46 
9.3. 
Method of Assignment to Treatment ..........................................................................46 
9.4. 
Rationale for Selection of Doses in the Study ............................................................46 
9.5. 
Special Treatment Considerations ..............................................................................46 
9.6. 
Prior and Concomitant Medications and Nonpharmacologic Procedures ..................47 
9.7. 
Prohibited Medications and Procedures .....................................................................47 
9.8. 
Vaccination .................................................................................................................48 
9.9. 
Treatment Compliance ................................................................................................48 
9.10. 
Contraception Guidance .............................................................................................49 
10. 
EFFICACY ASSESSMENTS ....................................................................................50 
10.1. 
Primary Efficacy Assessment .....................................................................................50 
10.2. 
Secondary Efficacy Assessments ...............................................................................50 
11. 
SAFETY ASSESSMENTS ........................................................................................51 
11.1. 
Demographic/Medical History ...................................................................................51 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 16 of 86 
CONFIDENTIAL 
11.1.1. 
Demographics and Baseline Characteristics ...............................................................51 
11.1.2. 
Disease Characteristics ...............................................................................................51 
11.1.3. 
Medical History ..........................................................................................................51 
11.2. 
Physical Examinations ................................................................................................51 
11.3. 
Vital Signs ..................................................................................................................52 
11.4. 
Laboratory Assessments .............................................................................................52 
11.4.1. 
Pregnancy Screen ........................................................................................................52 
11.4.2. 
Hematology .................................................................................................................53 
11.4.3. 
Serum Chemistry ........................................................................................................53 
11.4.4. 
Coagulation .................................................................................................................53 
11.4.5. 
Urinalysis and Urine Chemistry .................................................................................53 
11.5. 
Electrocardiograms .....................................................................................................53 
11.6. 
Immunogenicity ..........................................................................................................53 
11.7. 
Adverse Event Management .......................................................................................54 
11.7.1. 
Targeted Adverse Events ............................................................................................54 
11.7.2. 
Severity Assessment ...................................................................................................54 
11.7.3. 
Causality Assessment .................................................................................................55 
11.7.4. 
Serious Adverse Events ..............................................................................................56 
11.7.5. 
Suspected Unexpected Serious Adverse Reactions ....................................................56 
11.7.6. 
Collection and Reporting of Adverse Events .............................................................56 
11.7.6.1. 
All Adverse Events .....................................................................................................56 
11.7.6.2. 
Serious Adverse Events ..............................................................................................57 
11.7.7. 
Sponsor Reporting Requirements ...............................................................................57 
11.7.8. 
Investigator Reporting Requirements .........................................................................58 
11.8. 
Exposure During Pregnancy and Breastfeeding .........................................................58 
11.9. 
Safety Monitoring .......................................................................................................58 
12. 
PHARMACOKINETICS AND PHARMACODYNAMICS 
ASSESSMENTS .........................................................................................................59 
13. 
EXPLORATORY ASSESSMENTS ..........................................................................60 
13.1. 
Biomarker and APC Activity Assessments ................................................................60 
13.2. 
Genetics ......................................................................................................................60 
13.3. 
Additional Signs or Symptoms of aHUS and Resource Utilization ...........................60 
14. 
DATA QUALITY ASSURANCE ..............................................................................61 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 17 of 86 
CONFIDENTIAL 
14.1. 
Data Collection and Storage .......................................................................................61 
14.2. 
Records Retention .......................................................................................................62 
15. 
STATISTICAL METHODS AND PLANNED ANALYSES ...................................63 
15.1. 
General Considerations ...............................................................................................63 
15.2. 
Determination of Sample Size ....................................................................................64 
15.3. 
Analysis Sets ...............................................................................................................64 
15.4. 
Demographics and Baseline Characteristics ...............................................................64 
15.5. 
Patient Disposition ......................................................................................................64 
15.6. 
Prior and Concomitant Medications and Nonpharmacologic Therapies and 
Procedures ...................................................................................................................65 
15.7. 
Treatment Compliance ................................................................................................65 
15.8. 
Efficacy Analyses .......................................................................................................65 
15.8.1. 
Primary Efficacy Analysis ..........................................................................................65 
15.8.2. 
Key Secondary Efficacy Analyses ..............................................................................65 
15.8.2.1. 
Dialysis Requirement Status .......................................................................................65 
15.8.2.2. 
Time to Complete TMA Response .............................................................................65 
15.8.2.3. 
Complete TMA Response Status Over Time .............................................................66 
15.8.2.4. 
eGFR Value and Change from Baseline .....................................................................66 
15.8.2.5. 
CKD Stage ..................................................................................................................66 
15.8.2.6. 
Hematologic Parameters .............................................................................................66 
15.8.2.7. 
Hemoglobin Response ................................................................................................66 
15.8.2.8. 
Quality of Life ............................................................................................................66 
15.9. 
Safety Analyses ..........................................................................................................67 
15.9.1. 
Adverse Events ...........................................................................................................67 
15.9.2. 
Physical Examination and Vital Signs ........................................................................67 
15.9.3. 
Clinical Laboratory Tests ...........................................................................................67 
15.9.4. 
Electrocardiograms .....................................................................................................67 
15.9.5. 
Immunogenicity ..........................................................................................................68 
15.10. 
Pharmacokinetic/Pharmacodynamic Analyses ...........................................................68 
15.11. 
Exploratory Analyses ..................................................................................................68 
15.11.1. 
Biomarker and APC Activity Analyses ......................................................................68 
15.11.2. 
Genetics ......................................................................................................................68 
15.11.3. 
Additional Signs or Symptoms of aHUS and Resource Utilization ...........................69 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 18 of 86 
CONFIDENTIAL 
15.12. 
Other Statistical Issues ................................................................................................69 
15.12.1. 
Missing or Invalid Data ..............................................................................................69 
15.13. 
Interim Analyses .........................................................................................................69 
16. 
INFORMED CONSENT, ETHICAL REVIEW, AND REGULATORY 
CONSIDERATIONS ..................................................................................................70 
16.1. 
Informed Consent and Assent .....................................................................................70 
16.2. 
Data Monitoring Committee .......................................................................................70 
16.3. 
Ethical Review ............................................................................................................70 
16.4. 
Regulatory Considerations ..........................................................................................71 
16.4.1. 
Changes/Deviations to Protocol .................................................................................71 
16.5. 
Publication Policy .......................................................................................................71 
17. 
LIST OF REFERENCES ............................................................................................72 
18. 
APPENDICES ............................................................................................................73 
APPENDIX A. COMMON CREATININE REFERENCE INTERVALS .................................74 
APPENDIX B. ANTIBODY MEDIATED REJECTION CRITERIA .......................................75 
APPENDIX C. MANAGEMENT OF POTENTIAL DRUG INFUSION REACTIONS ..........76 
APPENDIX D. PROTOCOL LABORATORY TESTS .............................................................78 
APPENDIX E. EQ-5D-3L ..........................................................................................................79 
APPENDIX F. FACIT-FATIGUE ..............................................................................................82 
APPENDIX G. PEDIATRIC FACIT-FATIGUE .......................................................................83 
APPENDIX H. RESOURCE UTILIZATION PATIENT QUESTIONNAIRE .........................84 
APPENDIX I. PATIENT-REPORTED AHUS SYMPTOMS QUESTIONNAIRE ..................85 
APPENDIX J. GLOMERULAR FILTRATION RATE CATEGORY/STAGE IN 
CHRONIC KIDNEY DISEASE .................................................................................86 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 19 of 86 
CONFIDENTIAL 
LIST OF TABLES 
Table 1: 
Schedule of Study Visits and Assessments: Screening Through End of Initial 
Evaluation Period ........................................................................................................30 
Table 2: 
Schedule of Study Visits and Assessments: Extension Period Day 183 to 
Day 911 .......................................................................................................................33 
Table 3: 
Schedule of Study Visits and Assessments: Extension Period Day 967 to 
Day 1863 .....................................................................................................................35 
Table 4: 
Study Drug ..................................................................................................................44 
Table 5: 
Dosing Reference Chart for ALXN1210 Dose Preparation .......................................45 
Table 6: 
Loading and Maintenance Treatment Regimens ........................................................46 
Table 7: 
Adverse Event Severity Grading Scale .......................................................................55 
Table 8: 
Causality Assessment Descriptions ............................................................................55 
Table 9: 
Clinical Criteria for Diagnosing Anaphylaxis ............................................................77 
 
LIST OF FIGURES 
Figure 1: 
Study Design Schematic for Clinical Protocol ALXN1210-aHUS-311 .....................28 
 
  

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 20 of 86 
CONFIDENTIAL 
4. 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
 
Abbreviation 
Definition 
ADA 
antidrug antibodies 
ADAMTS13 
a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13  
ADL 
activities of daily living 
AEs 
adverse events 
aHUS 
atypical hemolytic uremic syndrome 
AMR 
antibody-mediated rejection  
APC 
alternative pathway of complement 
BMT 
bone marrow transplant 
BP 
blood pressure 
C5 
complement component 5 
CDF 
cumulative distribution function 
CFR 
Code of Federal Regulations 
CI 
confidence interval 
CKD 
chronic kidney disease 
CNI 
calcineurin inhibitor  
cRBC 
chicken red blood cell 
CSR 
Clinical Study Report 
CTCAE 
Common Terminology Criteria for Adverse Events 
DMC 
Data Monitoring Committee 
ECG 
Electrocardiogram 
eCRF 
electronic case report form 
EDC 
electronic data capture 
eGFR 
estimated glomerular filtration rate 
EOI 
end of infusion 
ESKD 
end-stage kidney disease  
EQ-5D-3L 
EuroQol 5 dimensions 3 level 
ET 
early termination 
FACIT 
functional assessment of chronic illness therapy 
FAS 
full analysis set 
FSH 
Follicle-stimulating hormone 
GCP 
good clinical practice 
GPV 
Global Pharmacovigilance 
Hib 
Haemophilus influenzae type b  
HIV 
human immunodeficiency virus 
HSCT 
hematopoietic stem cell transplant  
HUS 
hemolytic uremic syndrome 
IB 
Investigator’s Brochure 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation 
IEC 
Institutional (or Independent) Ethics Committee 
IRB 
Institutional Review Board 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 21 of 86 
CONFIDENTIAL 
Abbreviation 
Definition 
IV 
Intravenous 
IVIg 
intravenous immunoglobulin  
LDH 
lactate dehydrogenase 
LLN 
lower limit of normal 
LLT 
lowest level term 
MedDRA® 
Medical Dictionary for Regulatory Activities 
mITT 
modified Intent to Treat 
MMRM 
mixed model for repeated measures 
mTORi 
mammalian target of rapamycin inhibitor  
PD 
pharmacodynamic 
PEF 
peak expiratory flow 
PE/PI 
plasma exchange/plasma infusion 
PK 
pharmacokinetic 
PNH 
paroxysmal nocturnal hemoglobinuria 
PO 
orally 
PT 
preferred term 
QoL 
quality of life 
q8w 
once every 8 weeks 
SAEs 
serious adverse events 
SAP 
Statistical Analysis Plan 
SD 
standard deviation 
SLE 
systemic lupus erythematosus  
SOC 
system organ class 
SOPs 
standard operating procedures 
ST-HUS 
Shiga toxin-related hemolytic uremic syndrome 
sTNFR1 
soluble tumor necrosis factor receptor 1 
SUSAR 
suspected unexpected serious adverse reactions 
sVCAM-1 
soluble vascular adhesion molecule 1 
TEAEs 
treatment-emergent adverse events 
TMA 
thrombotic microangiopathy  
ULN 
upper limit of normal 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 22 of 86 
CONFIDENTIAL 
5. 
INTRODUCTION 
Atypical hemolytic uremic syndrome (aHUS) is a complement-mediated thrombotic 
microangiopathy (TMA), most often caused by mutations in genes encoding proteins involved in 
the alternative pathway of complement (APC) or by autoantibodies against APC regulatory 
proteins (Noris, 2010). Patients with aHUS are at risk for life-threatening manifestations of 
disease resulting from endothelial damage, including thrombocytopenia, intravascular hemolysis, 
acute renal failure, and extra-renal tissue damage. Importantly, approximately 20% of patients 
experience extra-renal manifestations of disease, including central nervous system, cardiac, 
gastrointestinal, distal extremity, and severe systemic organ involvement (Loirat, 2011; Brodsky, 
2015). Before the availability of eculizumab, mortality rates among patients with aHUS were as 
high as 15% during the acute progressing phase of the disease (Noris, 2010; Sellier-Leclerc, 
2007). Up to 50% of patients progressed to end-stage kidney disease (ESKD), often within a year 
of disease onset, and required dialysis or kidney transplant to sustain life. 
Chronic, uncontrolled terminal complement activation, specifically, activation of complement 
component 5 (C5) and dysregulation of complement activity, is central to the pathogenesis of 
aHUS and the devastating manifestations of this disease. As a result, the targeted blockade of C5, 
with selective inhibition of generation of C5a and C5b-9, represents an important therapeutic 
mechanism of treatment.  
Eculizumab (Soliris®) is the standard of care for aHUS patients. Eculizumab is a humanized 
monoclonal antibody that specifically binds to the complement protein C5 with high affinity. 
Eculizumab has no known off-target interactions with other proteins in vitro or in vivo. In 
addition, eculizumab is predicted to be effectorless, having no detectable binding to complement 
C1q or most Fcγ receptors (FcγR I, IIb/c IIIa, IIIb) and more than 10-fold weaker binding than 
an IgG1 isotype to FcγR IIa. Upon binding to the complement protein C5, eculizumab blocks 
cleavage to C5a and C5b by C5 convertase; which prevents generation of the terminal 
complement complex C5b-9. These attributes underlie the established safety and therapeutic 
efficacy profile of eculizumab as demonstrated in the 3 pivotal Phase 2 clinical studies (C10-003, 
C10-004, and C08-002A/B) and supported by subsequent postmarketing experiences.  
ALXN1210 and eculizumab are both recombinant, humanized monoclonal antibodies against 
human complement protein C5 sharing over 99% amino acid sequence homology. The goal of 
treatment with these complement inhibitors is to achieve immediate, complete, and sustained 
blockade of terminal complement activity. ALXN1210 is produced in Chinese hamster cells and 
was designed through minimal targeted engineering to substitute 4 amino acids in the 
eculizumab heavy chain to extend antibody half-life. These changes are designed to increase the 
half-life of ALXN1210 relative to eculizumab, increasing the duration of complete terminal 
complement inhibition, while preserving both the high degree of specificity for binding to C5 
and the effectorless nature of the antibody. 
Two studies of ALXN1210 are ongoing in patients with paroxysmal nocturnal hemoglobinuria 
(PNH) who are naïve to treatment with complement inhibitors. Study ALXN1210-PNH-103 is a 
Phase 1b, open-label, multiple dose study, and Study ALXN1210-PNH-201 is a Phase 2, 
open-label, multiple dose study. ALXN1210-PNH-103 is designed to assess dose ranging over a 
2-fold range of trough exposure levels, while Study ALXN1210-PNH-201 is designed to assess 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 23 of 86 
CONFIDENTIAL 
dose intervals of 4, 6, 8, and 12 weeks. Each study in patients with PNH also includes a 2-year 
extension phase. In addition, Study ALXN1210-HV-104 is being conducted to assess the 
pharmacokinetic (PK) profile of ALXN1210 in healthy Japanese subjects. 
Preliminary data from ALXN1210-PNH-103, indicate ALXN1210 treatment resulted in rapid 
reductions in lactate dehydrogenase (LDH) levels in 100% of patients, which were sustained 
through 2 to 4 monthly dosing intervals, consistent with the extended half-life (t½) of 
ALXN1210 (Lee, 2016). There was a notable decrease in the need for blood transfusions. These 
preliminary LDH data suggest that rapid, complete, and sustained complement inhibition with 
ALXN1210 results in highly effective blockade of intravascular hemolysis.  
More information about the PK, mechanism of action, known and expected benefits, risks, and 
reasonably anticipated adverse events (AEs) of ALXN1210 may be found in the current edition 
of the Investigator’s Brochure (IB). 
5.1. 
Benefits and Risks Assessment 
5.1.1. 
Potential Benefits 
ALXN1210 and eculizumab are recombinant, humanized monoclonal antibodies that bind the 
same epitope on complement protein C5 and deliver rapid, sustained, and specific inhibition of 
C5 activation and the terminal complement cascade through identical mechanisms of action. Due 
to its close pharmacological relationship to eculizumab and specificity for C5, ALXN1210 is 
anticipated to allow longer dosing intervals while having a safety and efficacy profile similar to 
eculizumab. While eculizumab is an effective therapy for the treatment of aHUS, chronic 
administration of the eculizumab regimen may pose an important burden to patients, many of 
whom have to miss days of work or school to accommodate once-every-2-week treatment. In 
some cases, patients may refuse treatment or are not compliant due to the frequency of treatment. 
Practice survey research supports the assumption that less frequent once-every-8-week infusions 
associated with ALXN1210 will have a positive impact on daily life for patients and their 
caregivers. 
5.1.2. 
Identified and Potential Risks 
5.1.2.1. 
Infections (N. Meningitidis and Other Encapsulated Organisms) 
Increased susceptibility to infection with encapsulated bacteria, particularly N. meningitidis, is a 
known risk associated with complement inhibition. Similar to eculizumab, the main risk 
associated with ALXN1210 is the risk of meningococcal infections. Specific risk mitigation 
measures are in place to address this risk, as described in Section 9.8. 
5.1.2.2. 
Immunogenicity 
Therapeutic proteins, including humanized mAbs like ALXN1210, may be associated with 
immunogenicity reactions. Consequently, monitoring of immunogenicity is in place for this 
study, as described in Section 7.3 and Section 11.6. No immunogenicity reactions have been 
observed to date in clinical studies with ALXN1210. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 24 of 86 
CONFIDENTIAL 
5.1.2.3. 
Pregnancy Exposure 
No studies of ALXN1210 have been conducted in pregnant women. Pregnant or nursing female 
patients are excluded from the clinical trial. Patients enrolled in the study, and their 
spouse/partner, will use a highly effective or acceptable method of contraception as required in 
Section 9.10. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 25 of 86 
CONFIDENTIAL 
6. 
STUDY OBJECTIVES AND ENDPOINTS 
6.1. 
Study Objectives 
6.1.1. 
Primary Objective 
The primary objective of the study is to assess the efficacy of ALXN1210 in complement 
inhibitor treatment naïve adolescent and adult patients with aHUS to inhibit 
complement-mediated TMA as characterized by thrombocytopenia, hemolysis, and renal 
impairment. 
6.1.2. 
Secondary Objectives 
The secondary objectives of the study are to assess the following: 
1. To characterize the safety and tolerability of ALXN1210 in this patient population 
2. To evaluate the efficacy of ALXN1210 by the following additional measures: 
a. Dialysis requirement status 
b. Time to Complete TMA Response 
c. Complete TMA Response status over time 
d. Observed value and change from baseline in estimated glomerular filtration rate 
(eGFR) 
e. Chronic kidney disease (CKD) stage, as evaluated by eGFR at select target days and 
classified as improved, stable (no change), or worsened compared to baseline 
f. Observed value and change from baseline in hematologic parameters (platelets, LDH, 
hemoglobin) 
g. Increase in hemoglobin of ≥ 20 g/L from baseline, observed at 2 separate assessments 
obtained at least 4 weeks (28 days) apart, and any measurement in between  
h. Change from baseline in quality of life (QoL), as measured by EuroQol 5 dimensions 
3 level (EQ-5D-3L; all patients), Functional Assessment of Chronic Therapy 
(FACIT) Fatigue version 4 (patients ≥ 18 years of age), and Pediatric FACIT Fatigue 
(patients < 18 years of age) questionnaires 
i. TMA parameters in patients who discontinue treatment but remain in the study 
3. To characterize the PK/pharmacodynamics (PD) of ALXN1210 by the following 
measures: 
a. Changes in serum ALXN1210 concentration over time  
b. Changes in free C5 concentrations over time 
c. Changes in free C5 and ALXN1210 concentration in patients who discontinue 
treatment but remain in the study 
4. To evaluate the long-term safety and efficacy of ALXN1210 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 26 of 86 
CONFIDENTIAL 
6.2. 
Endpoints 
6.2.1. 
Primary Efficacy Endpoint 
The primary efficacy endpoint of the study is Complete TMA Response during the 26-week 
Initial Evaluation Period, as evidenced by normalization of hematological parameters (platelet 
count and LDH) and ≥ 25% improvement in serum creatinine from baseline. Patients must meet 
all Complete TMA Response criteria at 2 separate assessments obtained at least 4 weeks (28 
days) apart, and any measurement in between. 
6.2.2. 
Secondary Efficacy Endpoints 
The secondary efficacy endpoints of the study are the following and will be measured through 26 
weeks and over the entire study period: 
1. Dialysis requirement status 
2. Time to Complete TMA Response 
3. Complete TMA Response status over time 
4. Observed value and change from baseline in eGFR 
5. CKD stage, as evaluated by eGFR at select target days and classified as improved, stable 
(no change), or worsened compared to baseline 
6. Observed value and change from baseline in hematologic parameters (platelets, LDH, 
hemoglobin) 
7. Increase in hemoglobin of ≥ 20 g/L from baseline, observed at 2 separate assessments 
obtained at least 4 weeks (28 days) apart, and any measurement in between 
8. Change from baseline in QoL, as measured by EQ-5D-3L (all patients), FACIT Fatigue 
version 4 (patients ≥ 18 years of age), and Pediatric FACIT Fatigue (patients < 18 years 
of age) questionnaires 
9. TMA parameters in patients who discontinue treatment but remain in the study 
6.2.3. 
Pharmacokinetic and Pharmacodynamic Endpoints 
The PK and PD endpoints of this study are the following: 
1. Changes in serum ALXN1210 concentration over time 
2. Changes in free C5 concentrations over time 
3. Changes in free C5 and ALXN1210 concentration in patients who discontinue treatment 
but remain in the study 
6.2.4. 
Safety Endpoints 
The safety and tolerability of ALXN1210 will be evaluated by physical examinations, vital signs, 
electrocardiograms (ECGs), laboratory assessments, and incidence of AEs and SAEs. The 
proportion of patients who develop antidrug antibodies (ADA) will also be assessed. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 27 of 86 
CONFIDENTIAL 
6.2.5. 
Exploratory Endpoints 
6.2.5.1. 
Biomarkers and APC Activity Endpoints 
Exploratory biomarkers of PD effect may include, but are not limited to, change from baseline in 
levels of markers of complement dysregulation (eg, Factor Ba), vascular inflammation 
(eg, soluble tumor necrosis factor receptor 1 [sTNFR1]), endothelial activation/damage (eg, 
soluble vascular adhesion molecule 1 [sVCAM-1], thrombomodulin), coagulation (eg, D-dimer), 
and renal injury (eg, cystatin C). Additional assessments may include measurements of 
ALXN1210 excretion in urine, chicken red blood cell (cRBC) hemolysis, total C5, 
autoantibodies to complement proteins (eg, anti-factor H) and APC activity (eg, Modified Ham’s 
test, complement deposition assays). 
6.2.5.2. 
Genetics Endpoints 
Exploratory genetics may be performed to investigate genetic variants in genes known to be 
associated with aHUS, as well as to identify novel genetic variants associated with aHUS, 
complement dysregulation, or metabolism or efficacy of ALXN1210. Patients (or legal 
guardians) may decline from providing a sample for exploratory genetics and still participate in 
the study. 
6.2.5.3. 
Additional Signs or Symptoms of aHUS and Resource Utilization 
Resource utilization will be assessed using the Resource Utilization Patient Questionnaire 
(Appendix H) and additional signs or symptoms of aHUS will be assessed using the Patient-
reported aHUS Symptoms Questionnaire (Appendix I).  
The Investigator will evaluate extra-renal signs or symptoms of aHUS using a composite of 
clinical laboratory measurements, vital signs, and an organ system review. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 28 of 86 
CONFIDENTIAL 
7. 
INVESTIGATIONAL PLAN 
7.1. 
Summary of Study Design 
Study ALXN1210-aHUS-311 is a Phase 3, open-label, single arm, multicenter study to evaluate 
the safety and efficacy of ALXN1210 administered by intravenous (IV) infusion to adolescent 
(12 to < 18 years of age) and adult (≥ 18 years of age) patients with aHUS. The study will enroll 
approximately 55 patients to receive ALXN1210. All patients must be naïve to complement 
inhibitor treatment and include at least 6 and up to 10 adolescent (12 to < 18 years of age at 
Screening) patients and at least 10 and up to 25 patients with prior kidney transplants. A 
minimum of 30 patients who meet all laboratory criteria for TMA (platelet count of < 150,000 
per microliter, LDH ≥ 1.5 × upper limit of normal (ULN), hemoglobin ≤ lower limit of normal 
(LLN), and serum creatinine level ≥ ULN) as determined by the central laboratory at Day 1, will 
be enrolled. 
The study consists of an up to 7 day Screening Period, a 26-week Initial Evaluation Period, and 
an Extension Period until the product is registered or approved (in accordance with 
country-specific regulations) or for up to 4.5 years, whichever occurs first. Dosages are based on 
the patient’s  body weight recorded at the last visit or more recently (Table 6). Patients will 
receive a loading dose of ALXN1210 IV (2400 mg for patients weighing ≥ 40 to < 60 kg, 2700 
mg for patients weighing ≥ 60 to < 100 kg, 3000 mg for patients weighing ≥ 100 kg) on Day 1, 
followed by maintenance doses of ALXN1210 IV (3000 mg for patients weighing ≥ 40 to < 60 
kg, 3300 mg for patients weighing ≥ 60 to < 100 kg, 3600 mg for patients weighing ≥ 100 kg) on 
Day 15 and once every 8 weeks (q8w) thereafter for a total of 26 weeks of treatment in the Initial 
Evaluation Period followed by maintenance doses q8w in the Extension Period (Figure 1). The 
end of trial is defined as the last patient’s last visit. 
Figure 1 illustrates the study design. 
 
Figure 1: 
Study Design Schematic for Clinical Protocol ALXN1210-aHUS-311 
 
 
7.2. 
Discussion of Design 
This Phase 3, open-label, single arm study will evaluate the safety and efficacy of treatment with 
ALXN1210. Although no formal comparison analyses are planned for this study, results from 
ALXN1210-treated patients will be evaluated in the context of results reported in eculizumab 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 29 of 86 
CONFIDENTIAL 
studies such as C10-004 trial, for which study design and conduct were similar to the current 
study.  
7.3. 
Schedule of Assessments 
The Schedule of Assessments for Screening and the Initial Evaluation Period is shown in 
Table 1. The Schedule of Assessments for the Extension Period is shown in Table 2. 
Refer to the Laboratory Manual for details on the number of samples and volumes for all 
sampling and tests during the study. 
Additional (unscheduled) visits outside the specified visits are permitted at the discretion of the 
Investigator. Procedures, tests, and assessments will be performed at the discretion of the 
Investigator. Any tests, procedures, or assessments performed at the Unscheduled Visits must be 
recorded on the electronic Case Report Forms (eCRFs). Local laboratory or central laboratory 
analysis may be used for Unscheduled Visit tests. However, if local laboratory tests are to be 
used, duplicate samples will be collected at the Unscheduled Visit for central laboratory testing.

Protocol ALXN1210-aHUS-311 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 30 of 86 
CONFIDENTIAL 
Table 1: 
Schedule of Study Visits and Assessments: Screening Through End of Initial Evaluation Period  
Period 
Screening 
Initial Evaluation Period 
Study Day 
–7 to –1 
1 
8 
15 
22 
29 
43 
57 
71 
85 
99 
113 
127 
141 
155 
169 
183x/ET 
Window (day) 
N/A 
 
±2 
±3 
±3 
±3 
±3 
±3 
±3 
±3 
±5 
±5 
±5 
±5 
±5 
±5 
±2 
Informed consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Confirmation or administration of meningococcal vaccinationa 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical history and demographics 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADAMTS13 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ST-HUS screenb 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Direct Coombs test 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Height 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pregnancy testc 
X 
X 
 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
FACIT-Fatigue questionnaire /Pediatric FACIT-Fatigue 
questionnaired,e 
 
X 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
X 
EQ-5D-3L questionnairee 
 
X 
X 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
X 
Patient-reported aHUS symptoms questionnairee 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Resource utilization patient questionnairee 
 
X 
 
 
 
X 
 
 
X 
 
 
 
X 
 
 
 
X 
Physical examination 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Abbreviated physical examinationf 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Assessment of extra-renal signs or symptoms of aHUS 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signsg 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety 12-Lead ECGh 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
X 
Chemistryi 
Xw 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
LDH isozymesj 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology including free hemoglobin and coagulationk 
Xw 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis and urine chemistry 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
X 
PK/PD samplingl 
 
Xl 
 
Xl 
 
Xl 
Xl 
Xl 
Xl 
Xl 
Xl 
Xl 
Xl 
Xl 
Xl 
Xl 
Xl 
Exploratory APC activitym 
 
X 
 
X 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Exploratory serum and plasma biomarkersn 
 
X 
 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
Exploratory urine biomarkerso 
 
X 
 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
Exploratory urine ALXN1210p 
 
X 
 
X 
 
X 
 
 
X 
 
 
 
 
 
 
 
 
Exploratory autoantibodyq 
 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
 
 
 
Exploratory genetic sampler 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Immunogenicity (ADA)s 
 
X 
 
 
 
 
 
 
X 
 
 
 
X 
 
 
 
X 
Review safety cardt 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medicationsu 
 
←Monitor continuously→ 
Adverse events 
 
←Monitor continuously→ 
ALXN1210 administrationv 
 
X 
 
X 
 
 
 
 
X 
 
 
 
X 
 
 
 
 
 

Protocol ALXN1210-aHUS-311 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 31 of 86 
CONFIDENTIAL 
Table 1: 
Schedule of Study Visits and Assessments: Screening Through End of Initial Evaluation Period (Continued) 
Abbreviations: ADA = antidrug antibody; ADAMTS13 = a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aHUS = atypical hemolytic uremic 
syndrome; APC = alternative pathway of complement; ECG = electrocardiogram; EOI = end of infusionEQ-5D-3L = EuroQol 5 dimensions 3 level; ET = early termination; 
FACIT = functional assessment of chronic illness therapy; HUS = hemolytic uremic syndrome; LDH = lactate dehydrogenase; N/A = not applicable; PD = pharmacodynamics; 
PK = pharmacokinetics; QoL = quality of life; ST-HUS = Shiga toxin-related hemolytic uremic syndrome 
a All patients must be vaccinated against meningococcal infections within 3 years prior to, or at the time of, initiating study drug. Patients who initiate study drug treatment less 
than 2 weeks after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic antibiotics until 2 weeks after vaccination. Patients who have not 
been vaccinated prior to initiating ALXN1210 treatment should receive prophylactic antibiotics prior to and for at least 2 weeks after meningococcal vaccination. 
b Stool sample.  
c Female patients of childbearing potential only. Serum pregnancy test at Screening and Day 183/ET; urine or serum pregnancy test at all other required time points. A negative 
pregnancy test result is required prior to administering study drug to female patients of childbearing potential at the indicated study visits. 
d FACIT Fatigue version 4 will be used for patients ≥ 18 years of age at Screening. Pediatric FACIT Fatigue will be used for patients < 18 years of age at Screening. 
e On dosing days, patient-reported assessments will be performed prior to dosing. 
f Abbreviated physical examination consists of a body system relevant examination based upon Investigator judgment and patient symptoms. At least 1 body system must be 
checked for an abbreviated examination. 
g Vital sign measurements will be taken after the patient has been resting for at least 5 minutes and will include systolic and diastolic BP (millimeters of mercury [mm Hg]), pulse 
oximetry, heart rate (beats/minute), respiratory rate (breaths/minute), and temperature (degrees Celsius [°C] or degrees Fahrenheit [°F]). On dosing days, vital signs will be taken 
predose. 
h Single 12-lead ECG will be collected at Screening, Day 57, and predose on Day 183 and any time on the ET visit day. Patients must be supine for approximately 5 to 10 minutes 
before ECG collection and remain supine but awake during ECG collection. 
i Clinical safety laboratory measurements will be collected predose on dosing days. LDH for eligibility will be determined from the chemistry assessment.  Follicle-stimulating 
hormone levels will be measured during Screening only in order to confirm postmenopausal status. 
j Serum sample for LDH isozyme testing will only be collected at selected sites at any/all timepoints prior to ALXN1210 dosing, dependent on sample testing availability. 
k Assessment for safety, as well as the primary and secondary endpoints. 
l Serum samples for PK/PD analyses will be collected at the indicated visits. For indicated visits falling on dosing days, samples will be collected predose (within 0.5 hours prior 
to the start of infusion) and at end of infusion (EOI) (within 0.5 hours after the EOI from the patient’s opposite, noninfused arm). In order to minimize needle sticks to the 
patient, the predose sample may be drawn through the venous access created for the dose infusion, prior to administration of the dose.  As noted, the postdose sample must be 
drawn from the opposite, noninfused arm. For indicated visits not falling on dosing days, samples may be collected at any time that visit day. All collection times will be 
recorded in the eCRF. 
m Collection will be predose on days of dosing and for days without dosing, at any time that visit day. All collection times will be recorded in the eCRF. 
n Collection will be predose. All collection times will be recorded in the eCRF.  
o Collection will be predose and combined with urine stabilizing buffer. All collection times will be recorded in the eCRF. 
p Urine sample for drug measurement will be collected at end of infusion (EOI) (within 0.5 hours after the EOI) on Days 1, 15, and 71; and at any time on Day 29. 
q Collection will be predose.  
r A single whole blood collection from those patients who consent to genetic testing can be collected anytime during the study.  
s ADA serum samples will be collected predose on Days 1, 71, and 127. Day 183 collection will occur prior to first dose in the Extension Period. Early termination collection will 
occur at any time on the ET visit day. All collection times will be recorded in the eCRF.  
t Review the Clinical Trial Participant Safety Information Card with the patient and discuss the importance of carrying the safety card at all times, and the risks ALXN1210 
treatment, including the risk of meningococcal infection.   
u Concomitant medications must be collected at all study visits and checked against the prohibited medication listed in Section 9.7. 

Protocol ALXN1210-aHUS-311 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 32 of 86 
CONFIDENTIAL 
Table 1: 
Schedule of Study Visits and Assessments: Screening Through End of Initial Evaluation Period (Continued) 
v The dose of ALXN1210 is based on the patient’s last recorded study visit body weight (Day 1 dosing is based on the body weight at Screening). 
w If a local laboratory is used to define eligibility, additional samples will be collected during the Screening Period for LDH, platelet count, hemoglobin and serum creatinine and 
tested at the central laboratory.  
x The primary efficacy endpoint assessment is before dosing on Day 183. Dosing on Day 183 is the start of the Extension Period. Please refer to additional Day 183 postdose 
assessments in Table 2. 
 

Protocol ALXN1210-aHUS-311 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 33 of 86 
CONFIDENTIAL 
Table 2: Schedule of Study Visits and Assessments: Extension Period Day 183 to Day 911 
Period 
Extension Period 
Study Day 
183p 
239 
295 
351 
407 
463 
519 
575 
631 
687 
743 
799 
855 
911 
Window (day) 
±2 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
Weight 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pregnancy testa 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
FACIT-Fatigue questionnaire /Pediatric FACIT-Fatigue questionnaireb,c 
 
 
 
X 
 
 
 
X 
 
 
X 
 
 
X 
EQ-5D-3L questionnairec 
 
 
 
X 
 
 
 
X 
 
 
X 
 
 
X 
Patient-reported aHUS symptoms questionnairec 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Resource utilization patient questionnairec 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Abbreviated physical examinationd 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Assessment of extra-renal signs or symptoms of aHUS 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signse 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Chemistry 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
LDH isozymesf 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology and coagulationg 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis and urine chemistry 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
PK/PD samplingh 
Xh 
 
 
Xh 
 
 
 
Xh 
 
 
Xh 
 
 
Xh 
Exploratory APC activityi 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Exploratory serum and plasma biomarkersj 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Exploratory urine biomarkersk 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Immunogenicity (ADA)l 
 
 
 
Xl 
 
 
 
Xl 
 
 
Xl 
 
 
Xl 
Review safety cardm 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medicationsn 
←Monitor continuously→ 
Adverse events 
←Monitor continuously→ 
ALXN1210 administrationo 
Xo 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Abbreviations: ADA = antidrug antibody; APC = alternative pathway of complement; aHUS = atypical hemolytic uremic syndrome; BP = blood pressure; eCRF = electronic case 
report form; EOI = end of infusion; EQ-5D-3L = EuroQol five dimensions 3 level; ET = early termination; FACIT = functional assessment of chronic illness therapy; 
LDH = lactate dehydrogenase; PD = pharmacodynamics; PK = pharmacokinetics; QoL = quality of life 
Note: For patients who terminate the study early, information on the assessments to be conducted on the ET visit day and further follow-up is provided in Table 3.  
Patients who discontinue ALXN1210 treatment, but remain in the study without treatment, should continue attending their scheduled protocol visits until Day 1863 (Section 8.3.2). 
For patients who discontinue ALXN1210 treatment, remain in the study, and further receive retreatment should undergo assessments as described in Section 8.3.2.1. 
a Female patients of childbearing potential only; urine or serum pregnancy test at all required time points. A negative pregnancy test result is required prior to administering 
ALXN1210 at the indicated study visits. 
b FACIT Fatigue version 4 will be used for patients ≥ 18 years of age at Screening. Pediatric FACIT Fatigue will be used for patients < 18 years of age at Screening. 
c On dosing days, patient-reported assessments will be performed prior to dosing. 
d Abbreviated physical examination consists of a body system relevant examination based upon Investigator judgment and patient symptoms. At least 1 body system must be 
checked for an abbreviated examination. 

Protocol ALXN1210-aHUS-311 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 34 of 86 
CONFIDENTIAL 
Table 2: Schedule of Study Visits and Assessments: Extension Period Day 183 to Day 911 (Continued) 
e Vital sign measurements will be taken after the patient has been resting for at least 5 minutes and will include systolic and diastolic BP (millimeters of mercury [mm Hg]), pulse 
oximetry, heart rate (beats/minute), respiratory rate (breaths/minute), and temperature (degrees Celsius [°C] or degrees Fahrenheit [°F]). On dosing days, vital signs will be taken 
predose. 
f Serum sample for LDH isozyme testing will only be collected at selected sites at any/all timepoints prior to ALXN1210 dosing, dependent on sample testing availability. 
g Assessment for safety, as well as the primary and secondary endpoints.  
h Serum samples for PK/PD analysis will be collected predose (within 0.5 hours prior to the start of infusion) and EOI (within 0.5 hours after the EOI) on Days 351, 575, 743, and 
911; EOI (within 0.5 hours after the EOI) on Day 183 . End of infusion samples will be drawn from the patient’s opposite, noninfused arm. In order to minimize needle sticks to 
the patient, the predose sample may be drawn through the venous access created for the dose infusion, prior to administration of the dose.  As noted, the postdose sample must be 
drawn from the opposite, noninfused arm. For patients who discontinue treatment but remain in the study, 1 PK/PD sample at any time will be collected as per protocol schedule 
until approximately 39 weeks after the last dose of ALXN1210. In case of retreatment, if the patient starts the retreatment on a scheduled visit which does not include PK/PD 
sample collection, PK/PD samples must be collected predose and at EOI. If a supplemental dose is administered, PK/PD samples will be collected predose and at EOI. All 
collection times will be recorded in the eCRF. 
i Collection will be predose on days of dosing and for days without dosing, at any time that visit day. All collection times will be recorded in the eCRF. 
j Collection will be predose on days of dosing and for days without dosing, at any time that visit day. All collection times will be recorded in the eCRF. 
k Collection will be predose on days of dosing and for days without dosing, at any time that visit day, and combined with urine stabilizing buffer. All collection times will be 
recorded in the eCRF.  
l A predose serum sample will be collected on Days 351, 575, 743, and Day 911. For patients who discontinue treatment but remain in the study, ADA sample will be collected at 
any time during the visits until approximately 39 weeks after the last dose of ALXN1210. In case of retreatment, if the patient starts the retreatment on a scheduled visit which 
does not include ADA sample collection, a predose ADA sample must be collected. If a supplemental dose is administered, a predose ADA sample will be collected. All 
collection times will be recorded in the eCRF.   
m Review the Clinical Trial Participant Safety Information Card with the patient and discuss the importance of carrying the safety card at all times, and the risks ALXN1210 
treatment, including the risk of meningococcal infection.   
n Concomitant medications must be collected at all study visits (and at the 56 [± 5]-day follow-up phone call for patients who terminate the study early) and checked against the 
prohibited medication listed in Section 9.7. 
o Extension Period begins at the start of Day 183 dosing. The dose of ALXN1210 is based on the patient’s body weight recorded at the last visit or more recently. For patients who 
discontinue ALXN1210 treatment, remain in the study, and further receive retreatment, the dosing details are provided in Section  8.3.2.1. 
 
 

Protocol ALXN1210-aHUS-311 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 35 of 86 
CONFIDENTIAL 
Table 3: Schedule of Study Visits and Assessments: Extension Period Day 967 to Day 1863 
Period 
Extension Period 
Study Day 
967 
1023 
1079 
1135 
1191 
1247 
1303 
1359 
1415 
1471 
1527 
1583 
1639 
1695 
1751 
1807 
1863/ 
ET/EOS 
Window (day) 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
±7 
Weight 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Pregnancy testa 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
FACIT-Fatigue questionnaire 
/Pediatric FACIT-Fatigue 
questionnaireb,c 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
EQ-5D-3L questionnairec 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
Physical examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Abbreviated physical examinationd 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Assessment of extra-renal signs or 
symptoms of aHUS 
 
 
 
X 
 
 
 
X 
 
 
 
X 
 
 
 
X 
X 
Vital signse 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Safety 12-Lead ECGf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Chemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
LDH isozymesg 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology and coagulationh 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Urinalysis and urine chemistry 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
PK/PD samplingi 
 
 
Xi 
 
 
Xi 
 
 
Xi 
 
 
 
Xi 
 
 
Xi 
Xi 
Exploratory APC activityj 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Exploratory serum and plasma 
biomarkersk 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Exploratory urine biomarkersl 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Immunogenicity (ADA)m 
 
 
Xm 
 
 
Xm 
 
 
Xm 
 
 
 
Xm 
 
 
Xm 
Xm 
Review safety cardn 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medicationso 
←Monitor continuously→ 
Adverse events 
←Monitor continuously→ 
ALXN1210 administrationp 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Abbreviations: ADA = antidrug antibody; APC = alterative pathway of complement; aHUS = atypical hemolytic uremic syndrome; BP = blood pressure; 
ECG = electrocardiogram; eCRF = electronic case report form; EOI = end of infusion; EOS = end of study; EQ-5D-3L = EuroQol five dimensions 3 level; ET = early termination; 
FACIT = functional assessment of chronic illness therapy; LDH = lactate dehydrogenase; PD = pharmacodynamics; PK = pharmacokinetics; QoL = quality of life 
Note: If a patient terminates from the study early, ET assessments will be conducted as soon as possible. A follow-up phone call will be performed 8 weeks (56 days) ± 5 days 
following the patient’s last dose of ALXN1210 to collect information on concomitant medications, nonpharmacological therapies and procedures, and adverse events.  
Patients who discontinue ALXN1210 treatment, but remain in the study without treatment, should continue attending their scheduled protocol visits until Day 1863 (Section 8.3.2). 
For patients who discontinue ALXN1210 treatment, remain in the study, and further receive retreatment should undergo assessments as described in Section 8.3.2.1. 
a Female patients of childbearing potential only. Serum pregnancy test on the ET visit day only; urine or serum pregnancy test at all other required time points. A negative 
pregnancy test result is required prior to administering ALXN1210 to female patients of childbearing potential at the indicated study visits. 
b FACIT Fatigue version 4 will be used for patients ≥ 18 years of age at Screening. Pediatric FACIT Fatigue will be used for patients < 18 years of age at Screening. 

Protocol ALXN1210-aHUS-311 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 36 of 86 
CONFIDENTIAL 
Table 3: Schedule of Study Visits and Assessments: Extension Period Day 967 to Day 1863 (Continued) 
c On dosing days, patient-reported assessments will be performed prior to dosing. 
d Abbreviated physical examination consists of a body system relevant examination based upon Investigator judgment and patient symptoms. At least 1 body system must be 
checked for an abbreviated examination. 
e Vital sign measurements will be taken after the patient has been resting for at least 5 minutes and will include systolic and diastolic BP (millimeters of mercury [mm Hg]), pulse 
oximetry, heart rate (beats/minute), respiratory rate (breaths/minute), and temperature (degrees Celsius [°C] or degrees Fahrenheit [°F]). On dosing days, vital signs will be taken 
predose. 
f Single 12-lead ECG will be collected at Day 1863 or ET. Patients must be supine for approximately 5 to 10 minutes before ECG collection and remain supine but awake during 
ECG collection. 
g Serum sample for LDH isozyme testing will only be collected at selected sites at any/all timepoints prior to ALXN1210 dosing, dependent on sample testing availability. 
h Assessment for safety, as well as the primary and secondary endpoints.  
i Serum samples for PK/PD analysis will be collected predose (within 0.5 hours prior to the start of infusion) and EOI (within 0.5 hours after the EOI) on Days 1079, 1247, 1415, 
1639, and 1807; and at any time on Day 1863 or ET. End of infusion samples will be drawn from the patient’s opposite, noninfused arm. In order to minimize needle sticks to the 
patient, the predose sample may be drawn through the venous access created for the dose infusion, prior to administration of the dose. As noted, the postdose sample must be 
drawn from the opposite, noninfused arm. For patients who discontinue treatment, but remain in the study, 1 PK/PD sample at any time will be collected as per protocol schedule 
until approximately 39 weeks after the last dose of the study drug. In case of retreatment, if the patient starts the retreatment on a scheduled visit which does not include PK/PD 
sample collection, PK/PD samples must be collected predose and at EOI. If a supplemental dose is administered, PK/PD samples will be collected predose and at EOI. All 
collection times will be recorded in the eCRF. 
j Collection will be predose on days of dosing and for days without dosing, at any time that visit day. All collection times will be recorded in the eCRF. 
k Collection will be predose on days of dosing and for days without dosing, at any time that visit day. All collection times will be recorded in the eCRF. 
l Collection will be predose on days of dosing and for days without dosing, at any time that visit day, and combined with urine stabilizing buffer. All collection times will be 
recorded in the eCRF.  
m A predose serum sample will be collected on Days 1079, 1247, 1415, 1639, and 1807. A serum sample will also be collected at any time on Day 1863 or ET. For patients who 
discontinue treatment but remain in the study, ADA sample will be collected at any time during the visits until approximately 39 weeks after the last dose of ALXN1210. In case 
of retreatment, if the patient starts the retreatment on a scheduled visit which does not include ADA sample collection, a predose ADA sample must be collected. If a 
supplemental dose is administered, a predose ADA sample will be collected. All collection times will be recorded in the eCRF. 
n Review the Clinical Trial Participant Safety Information Card with the patient and discuss the importance of carrying the safety card at all times, and the risks ALXN1210 
treatment, including the risk of meningococcal infection.   
o Concomitant medications must be collected at all study visits (and at the 56 [± 5]-day follow-up phone call for patients who terminate the study early) and checked against the 
prohibited medication listed in Section 9.7. 
p The dose of ALXN1210 is based on the patient’s body weight recorded at the last visit or more recently. For patients who discontinue ALXN1210 treatment, remain in the study, 
and further receive retreatment, the dosing details are provided in Section 8.3.2.1. 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 37 of 86 
CONFIDENTIAL 
8. 
STUDY POPULATION 
A total of approximately 55 patients with documented aHUS will be enrolled and assigned to 
treatment with ALXN1210 at approximately 200 investigative sites globally. The study will 
enroll at least 6 and up to 10 adolescent (12 to < 18 years of age at Screening) patients and at 
least 10 and up to 25 patients with prior kidney transplants. A minimum of 30 patients who meet 
all laboratory criteria for TMA (platelet count of < 150,000 per microliter, LDH ≥ 1.5 × upper 
limit of normal (ULN), hemoglobin ≤ lower limit of normal (LLN), and serum creatinine level ≥ 
ULN) as determined by the central laboratory at Day 1, will be enrolled. 
Individuals who do not satisfy the criteria for participation in this study (screen failure) may be 
rescreened based on discussion and agreement between the Investigator and the Medical 
Monitor. Patients may be rescreened a maximum of 2 times. 
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
8.1. 
Inclusion Criteria 
Patients are eligible for enrollment in the study only if they meet all of the following criteria and 
none of the exclusion criteria: 
1. Male or female patients ≥ 12 years of age and weighing ≥ 40 kg at the time of consent. 
2. Evidence of TMA, including thrombocytopenia, evidence of hemolysis, and kidney 
injury, based on the following laboratory findings: 
a. Platelet count < 150,000 per microliter (µL) during the Screening Period or within 28 
days prior to the start of the Screening Period, and 
b. LDH ≥ 1.5 × upper limit of normal (ULN) during the Screening Period or within 28 
days prior to the start of the Screening Period, and hemoglobin ≤ lower limit of 
normal (LLN) for age and gender during the Screening Period or within 28 days prior 
to the start of the Screening Period, and 
c. Serum creatinine level ≥ ULN during the Screening Period in adults (≥ 18 years of 
age), or ≥ 97.5th percentile for age (Appendix A) at Screening in adolescents (12 to 
< 18 years of age) (patients who require dialysis for acute kidney injury are also 
eligible). 
3. Among patients with a kidney transplant: 
a. Known history of aHUS prior to current kidney transplant, or 
b. No known history of aHUS, and persistent evidence of TMA at least 4 days after 
modifying the immunosuppressive regimen (eg, suspending or reducing the dose) of 
calcineurin inhibitor ([CNI]; eg, cyclosporine, tacrolimus) or mammalian target of 
rapamycin inhibitor ([mTORi]; eg, sirolimus, everolimus). 
4. Among patients with onset of TMA postpartum, persistent evidence of TMA for > 3 days 
after the day of childbirth. 
5. To reduce the risk of meningococcal infection (Neisseria meningitidis), all patients must 
be vaccinated against meningococcal infections within 3 years prior to, or at the time of, 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 38 of 86 
CONFIDENTIAL 
initiating study drug. Patients who receive a meningococcal vaccine less than 2 weeks 
before initiating ALXN1210 treatment must receive treatment with appropriate 
prophylactic antibiotics until 2 weeks after vaccination. Patients who have not been 
vaccinated prior to initiating ALXN1210 treatment should receive prophylactic 
antibiotics prior to and for at least 2 weeks after meningococcal vaccination. 
6. Patients < 18 years of age must have been vaccinated against Haemophilus influenzae 
type b (Hib) and Streptococcus pneumoniae according to national and local vaccination 
schedule guidelines. 
7. Female patients of childbearing potential and male patients with female partners of 
childbearing potential must follow protocol-specified guidance (Section 9.10) for 
avoiding pregnancy while on treatment and for 8 months after last dose of study drug. 
8. Willing and able to give written informed consent and comply with the study visit 
schedule. For patients < 18 years of age, patient's legal guardian must be willing and able 
to give written informed consent and the patient must be willing to give written informed 
assent (if applicable as determined by the central or local Institutional Review Board 
[IRB]/ Institutional (or Independent) Ethics Committee [IEC]). 
Evaluation of Inclusion Criteria 2a and 2b may be based on local laboratory results within 28 
days prior to the start of the Screening Period or laboratory results obtained during the Screening 
Period from a local or central laboratory. If a local laboratory is used to define eligibility, 
additional samples will be collected during the Screening Period for LDH, platelet count, 
hemoglobin and serum creatinine and tested at the central laboratory.  If patients are found to not 
meet the eligibility criteria for serum creatinine (Inclusion Criterion 2c) based on central 
laboratory results, they must not be enrolled into the study; if the subject has received the first 
dose of ALXN1210 the patient must be withdrawn from the study, and may be replaced. All 
analyses in this study will be based on results from the central laboratory. A central laboratory 
result for Inclusion Criterion 2c may not be available prior to first dose; results received after the 
first dose indicating that eligibility is not satisfied could lead to discontinuation and replacement 
of the patient. 
8.2. 
Exclusion Criteria 
Patients will be excluded from study enrollment if they meet any of the following criteria: 
1. Known familial or acquired ‘a disintegrin and metalloproteinase with a thrombospondin 
type 1 motif, member 13’ (ADAMTS13) deficiency (activity < 5%). Eligibility may be 
defined using results from tests carried out as standard of care for the treatment of the 
current TMA prior to a patient giving informed consent. In these cases informed consent 
will be provided prior to collecting the data for the trial. 
2. Known Shiga toxin-related hemolytic uremic syndrome (ST-HUS) as demonstrated by a 
positive test for Shiga toxin or culture of Shiga toxin producing bacteria. Eligibility may 
be defined using results from tests carried out as standard of care for the treatment of the 
current TMA prior to a patient giving informed consent. In these cases informed consent 
will be provided prior to collecting the data for the trial. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 39 of 86 
CONFIDENTIAL 
3. Positive direct Coombs test. Eligibility may be defined using results from tests carried out 
as standard of care for the treatment of the current TMA prior to a patient giving 
informed consent. In these cases informed consent will be provided prior to collecting the 
data for the trial. 
4. Known Human Immunodeficiency Virus (HIV) infection. 
5. Unresolved meningococcal disease. 
6. Patients with a confirmed diagnosis of ongoing sepsis defined as positive blood cultures 
within 7 days prior to the start of Screening and untreated with antibiotics. 
7. Presence or suspicion of active and untreated systemic bacterial infection that, in the 
opinion of the Investigator, confounds an accurate diagnosis of aHUS or impedes the 
ability to manage the aHUS disease. 
8. Pregnancy or breastfeeding. 
9. Heart, lung, small bowel, pancreas, or liver transplant. 
10. Among patients with a kidney transplant, acute kidney dysfunction within 4 weeks of 
transplant consistent with the diagnosis of acute antibody-mediated rejection (AMR) 
according to Banff 2013 criteria (Appendix B). 
11. Among patients without a kidney transplant, history of kidney disease other than aHUS, 
such as: 
a. Known kidney biopsy finding suggestive of underlying disease other than aHUS 
b. Known kidney ultrasound finding consistent with an alternative diagnosis to aHUS 
(eg small kidneys for age) 
c. Known family history and/or genetic diagnosis of noncomplement mediated genetic 
renal disease (eg, focal segmental glomerulosclerosis) 
12. Identified drug exposure-related HUS. 
13. Receiving PE/PI, for 28 days or longer, prior to the start of Screening for the current 
TMA. 
14. History of malignancy within 5 years of Screening with the exception of a nonmelanoma 
skin cancer or carcinoma in situ of the cervix that has been treated with no evidence of 
recurrence. 
15. Bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) within the 
last 6 months prior to the start of Screening. 
16. HUS related to known genetic defects of cobalamin C metabolism. 
17. Known systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or 
antiphospholipid antibody positivity or syndrome. 
18. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy for 
ESKD). 
19. Patients receiving chronic intravenous immunoglobulin (IVIg) within 8 weeks prior the 
start of Screening, unless for unrelated medical condition (eg, hypogammaglobinemia); 
or chronic rituximab therapy within 12 weeks prior to the start of Screening. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 40 of 86 
CONFIDENTIAL 
20. Patients receiving other immunosuppressive therapies such as steroids, mTORi (eg, 
sirolimus, everolimus), CNI (eg, cyclosporine or tacrolimus) are excluded unless:  
a. part of an established post-transplant antirejection regimen, or  
b. patient has confirmed anti-complement factor antibodies requiring 
immunosuppressive therapy, or  
c. steroids are being used for a condition other than aHUS (eg, asthma). 
21. Participation in another interventional treatment study or use of any experimental therapy 
within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives 
of that investigational product, whichever is greater. 
22. Prior use of eculizumab or other complement inhibitors. 
23. Hypersensitivity to any ingredient contained in the study drug, including hypersensitivity 
to murine proteins. 
24. Any medical or psychological condition that, in the opinion of the Investigator or 
Sponsor, could increase the risk to the patient by participating in the study or confound 
the outcome of the study.  
25. Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to 
the start of Screening. 
26. Use of tranexamic acid within 7 days prior to Screening is prohibited. 
Laboratory results for Exclusion Criterion number 1 and/or Exclusion Criterion number 2 may 
not be available prior to first dose. Later results for Exclusion Criterion number 1 and/or 
Exclusion Criterion number 2 could lead to discontinuation and replacement of the patient 
(please refer to Section 8.3 for potential discontinuation and replacement details). 
8.3. 
Discontinuation 
8.3.1. 
Early Termination of Patients From the Study 
The criteria for early termination of patients from the study include: 
• Withdrawal of consent: A patient has the right to withdraw from the study at any 
time.  
• Patient with prior kidney transplant developing AMR (C4d positive renal biopsy) and 
for whom rituximab is deemed the appropriate therapy: patient must be terminated 
from the study and receive standard of care therapy. 
• Intake of certain prohibited medications as described in Section 9.7. 
• Patient who is receiving ALXN1210 as a part of retreatment (Section 8.3.2.1) chooses 
to discontinue ALXN1210. 
• The Sponsor Medical Monitor or the Investigator deems it is in the best interest of the 
patient. 
If a patient terminates from the study early, the Sponsor and site monitor will be notified and the 
assessments specified for the Early Termination (ET) visit (as shown in the Schedule of 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 41 of 86 
CONFIDENTIAL 
Assessments, Section 7.3, Table 3) will be performed as soon as possible. In addition, a follow-
up phone call will be performed 8 weeks (56 days) ± 5 days following the patient’s last dose of 
ALXN1210, to collect concomitant medications, nonpharmacological therapies and procedures, 
and AEs.  
At the time of the termination, if there is an ongoing AE or an unresolved laboratory result that 
in the opinion of the investigator, is significantly outside of the reference range and clinically 
significant (Section 11.4), the Investigator will attempt to provide follow-up until a satisfactory 
clinical resolution of the laboratory result or AE is achieved. 
The reason for early termination will be recorded on the eCRF. 
Patients who terminate early from the study will not be replaced.  
8.3.2. 
Discontinuation of ALXN1210 Treatment and Continuation in the Study 
Patients who discontinue ALXN1210 treatment will be allowed to continue in the study for the 
remainder of the visits without receiving ALXN1210 dosing. 
Patients should be permanently discontinued from ALXN1210 treatment if any of the following 
occur during the study: 
• Serious infusion reaction (such as bronchospasm with wheezing or requiring 
ventilator support or symptomatic hypotension, refer to Appendix C) or serum 
sickness-like reactions manifesting 1 to 14 days after drug administration; 
• Pregnancy or planned pregnancy; or 
• The Sponsor Medical Monitor or the Investigator deems it is in the best interest of the 
patient. 
The Investigator should notify the Medical Monitor as soon as possible prior to discontinuing a 
patient’s study treatment and provide the rationale for discontinuing.  
If a patient is discontinued from ALXN1210 treatment, but remains in the study, patient should 
continue attending his or her scheduled protocol visits until Day 1863. During these visits, all 
assessments except for ALXN1210 administration as described in the Schedule of Assessments 
(Table 1, Table 2, and Table 3) should be performed. The PK/PD (1 sample at any time) and 
ADA samples will be collected as per protocol schedule until about 39 weeks after the last dose 
of the study drug.  
Any patient who discontinues the ALXN1210 treatment but remains in the study and develops 
abnormal TMA parameter (as specified in Section 8.3.2.1) before Day 1863, will have the 
opportunity for retreatment (Section 8.3.2.1). If the study drug is discontinued again (after 
retreatment), then the patient will be terminated from the study and ET procedures and follow-up 
will be performed as described in Section 8.3.1. 
The reason for the treatment discontinuation will be recorded on the eCRF.  
If a female patient is permanently discontinued from ALXN1210 treatment due to pregnancy, the 
Investigator will attempt to follow-up until the outcome of the pregnancy (Section 11.8). 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 42 of 86 
CONFIDENTIAL 
8.3.2.1. 
Retreatment of Patients who Discontinue ALXN1210 Treatment 
A patient who discontinues ALXN1210 treatment, but remains in the study, and develops 
abnormal TMA parameter (as indicated by criteria No. 1 below) before Day 1863, may be 
restarted on ALXN1210, if all 3 conditions below are fulfilled: 
1. Evidence of TMA, including thrombocytopenia, evidence of hemolysis, or kidney injury 
based on any one of the following laboratory findings: 
• Platelet count < 150,000/μL, or 
• LDH > 1.5 × ULN with hemoglobin ≤ LLN for age and gender, or 
• Serum creatinine ≥ ULN in adults (≥ 18 years of age), or ≥ 97.5th percentile for age 
(Appendix A) in adolescents (12 to < 18 years of age). 
Note: The TMA laboratory parameter must be confirmed on at least one repeated 
measure. The above laboratory results can be obtained at either the central laboratory 
(preferable) or the site’s local laboratory. 
2. The Investigator believes that the patient will potentially benefit from retreatment, 
initiates a discussion with the Sponsor Medical Monitor, and provides a medically 
justified rationale. The Investigator and Medical Monitor mutually agree on retreatment, 
and the decision is documented. 
3. The patient agrees to the consent addendum for retreatment. 
If the decision to re-treat with ALXN1210 occurs on a scheduled study visit, then dosing may 
begin on that day. 
• Patient will receive a loading dose of ALXN1210 IV based on the weight recorded at 
the last visit or more recently (2400 mg for patients weighing ≥ 40 to < 60 kg, 
2700 mg for patients weighing ≥ 60 to < 100 kg, 3000 mg for patients weighing 
≥ 100 kg). All assessments will be performed per the protocol schedule (Table 2 and 
Table 3). If start of the retreatment occurs on a visit which does not include PK/PD 
sample collection, PK/PD samples will be collected predose and at EOI, along with a 
predose ADA sample. 
• Two weeks after the loading dose, the patient will receive a supplemental 
maintenance dose of ALXN1210 IV at an unscheduled visit, based on the weight at 
the last visit or more recently (≥ 40 to < 60 kg = 3000 mg; 
≥ 60 to < 100 kg = 3300 mg; ≥ 100 kg = 3600 mg). An abbreviated physical 
examination will be conducted, vital signs will be collected, and the safety card will 
be reviewed with the patient. Pharmacokinetic/PD samples will be collected predose 
and at EOI along with a predose ADA sample.  
• Six weeks after the supplemental maintenance dose, the patient will return to the site 
at the scheduled study visit. At this visit, patient will receive maintenance dose of 
ALXN1210, undergo all assessments per the protocol schedule (Table 2 and Table 3), 
and then continue to attend the visits every 8 weeks per the protocol schedule. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 43 of 86 
CONFIDENTIAL 
If the decision to re-treat with ALXN1210 occurs between scheduled study visits: 
• A supplemental loading dose of ALXN1210 may be administered. An abbreviated 
physical examination will be conducted, vital signs will be collected, and the safety 
card will be reviewed with the patient. Pharmacokinetic/PD samples will be collected 
predose and at EOI along with a predose ADA sample. 
• The Medical Monitor and the Investigator will determine administration of 
maintenance dose of ALXN1210 further to facilitate alignment with Schedule of 
Assessment (Table 2 and Table 3) as appropriate. The timing of subsequent visits 
may be modified to accommodate realignment to Schedule of Assessment, these will 
not be considered deviations to visit windows. 
8.3.3. 
Discontinuation of Study/Site Termination by Sponsor or Health Authority 
The Sponsor or Health Authority may terminate the study for reasonable cause. Conditions that 
may warrant termination of the study include, but are not limited to:  
• Discovery of an unexpected, serious, or unacceptable risk to patients enrolled in the 
study  
• Sponsor decision to suspend or discontinue testing, evaluation, or development of the 
study drug  
• Failure of the Investigator to comply with the approved protocol, pertinent guidelines, 
and/or regulations  
• Submission of knowingly false information from the Investigator to the Sponsor 
and/or regulatory authorities 
Should the study be terminated early, the Sponsor will notify the national competent authority 
and the IRB/IEC according to local requirements. 
8.3.4. 
Replacements 
If it is determined at any point that a patient’s Screening data does not satisfy Inclusion Criterion 
number 2c, Exclusion Criterion number 1, and/or Exclusion Criterion number 2, after receiving 
at least 1 dose of investigational product (eg, patient local laboratory data used to confirm 
eligibility criteria are subsequently determined by a central laboratory to no longer satisfy 
eligibility criteria), the patient will be discontinued from the study and may be replaced. Early 
termination procedures will be performed on patients who are terminated early (Section 8.3.1) 
and all AEs will be collected until 56 days after the patient’s last dose of study drug 
(Section 11.7.6.1). 
As described in Section 15.3, the Full Analysis Set (FAS) will be based on a modified intent to 
treat (mITT) approach, and the patients discontinued from the study for the reasons described 
above will be excluded from the FAS. The aim of the replacement process is to yield a FAS that 
includes the planned number of patients all satisfying key inclusion and exclusion criteria. 
8.3.5. 
End of Study Definition 
The end of the study is defined as the date of the last patient’s last visit in the Extension Period. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 44 of 86 
CONFIDENTIAL 
9. 
STUDY TREATMENT 
9.1. 
Materials and Supplies 
9.1.1. 
Description of Study Drugs 
ALXN1210, a recombinant, humanized anti-C5 monoclonal antibody composed of two 448 
amino acid heavy chains and two 214 amino acid light chains, is an IgG2/4 kappa 
immunoglobulin consisting of human constant regions, and murine complementarity-
determining regions grafted onto human framework light- and heavy-chain variable regions. 
ALXN1210 is produced in Chinese hamster cells and was designed through minimal targeted 
engineering of eculizumab by introducing 4 unique amino acid substitutions to its heavy chain to 
extend antibody half-life. ALXN1210 and eculizumab share over 99% primary amino acid 
sequence identity and have very similar pharmacology. 
ALXN1210 drug product is supplied for clinical studies as a sterile, preservative-free 10-mg/mL 
solution in single-use vials and designed for infusion by diluting into commercially available 
saline (0.9% sodium chloride injection; country-specific pharmacopeia) for administration via IV 
infusion. 
Refer to Table 4 and the current IB for additional information.  
Table 4: 
Study Drug 
Product Name 
ALXN1210 
Dosage Form 
Concentrated solution (10 mg/mL) for infusion 
Route of Administration 
Intravenous infusion 
Physical Description 
Clear to translucent, slight whitish color, practically free from particles 
Manufacturer 
Alexion Pharmaceuticals, Inc. or Contracted Manufacturing Organization 
9.1.2. 
Study Drug Packaging and Labeling 
ALXN1210 is packaged in United States Pharmacopeia (USP)/ European Union Pharmacopeia 
(EP) Type 1 borosilicate glass vials and stoppered with a butyl rubber stopper with an aluminum 
overseal and a flip-off cap. Study drug will be supplied in kits. Please refer to the ALXN1210 
Pharmacy Manual for details. 
ALXN1210 orders will be released to each site upon receipt of all required documents based 
upon applicable regulations and once the site is activated in IXRS®. 
9.1.3. 
Study Drug Storage 
Upon arrival of the study drug kits at the study site, the pharmacist (or trained designee) should 
promptly remove the study drug kits from the shipping cooler and store them in their original 
cartons under refrigerated conditions at 2°C to 8°C (35°F to 47°F) and protected from light. 
ALXN1210 should not be frozen. Study drug must be stored in a secure, limited-access storage 
area, and the temperature must be monitored daily.  
The admixed drug product should be at room temperature prior to administration. The material 
must not be heated (eg, by using a microwave or other heat source) other than by ambient air 
temperature. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 45 of 86 
CONFIDENTIAL 
Please consult the Pharmacy Manual for further information regarding the storage conditions of 
reconstituted ALXN1210. 
9.1.4. 
Study Drug Preparation and Infusion 
ALXN1210 must NOT be administered as an IV push or bolus injection. Infusions of study 
drug should be prepared using aseptic technique. The patient’s required dose of ALXN1210 will 
be further diluted into commercially available saline (0.9% sodium chloride; country-specific 
pharmacopeia) at the volume specified in Table 5. ALXN1210 admixture will be administered to 
the patient using an IV tubing administration set via an infusion pump. Use of a 0.2 micron filter 
is required during infusion.  
Table 5: 
Dosing Reference Chart for ALXN1210 Dose Preparation 
Dose Type 
Body Weight 
(kg)a 
Dose 
(mg) 
ALXN1210 
Volume (mL) 
Saline 
Volume 
(mL) 
Total 
Volume 
(mL) 
Minimum 
Infusion 
Duration 
minutes 
(hours) 
Maximum 
Infusion 
Rate 
(mL/hour) 
Loading 
 
 
≥ 40 to < 60 
2400 
240 
240 
480 
114 (1.9) 
253 
≥ 60 to < 100 
2700 
270 
270 
540 
102 (1.7) 
318 
≥ 100 
3000 
300 
300 
600 
108 (1.8) 
333 
Maintenance 
 
 
≥ 40 to < 60 
3000 
300 
300 
600 
140 (2.4) 
250 
≥ 60 to < 100 
3300 
330 
330 
660 
120 (2.0) 
330 
≥ 100 
3600 
360 
360 
720 
132 (2.2) 
328 
Please refer to the Pharmacy Manual for additional dose preparation instructions.  
a Body weight as recorded at the last study visit or more recently. 
Doses of study drug must only be prepared and dispensed by qualified study personnel. Study 
drug is to be dispensed only to enrolled patients who are confirmed eligible for participation in 
this study. Once study drug is prepared for a patient, it can only be administered to that patient. 
Vials of study drug are for one-time use only and any drug product remaining in the vial should 
not be used for another patient. Any drug remaining in the infusion tubing or infusion bag should 
not be used for another patient. 
Further details on preparation and dose administration of ALXN1210, as well as disposal of 
study drug, can be found in the Pharmacy Manual.  
9.1.5. 
Study Drug Handling and Disposal 
All clinical study material provided to the Investigator will be stored in a secure place, and 
allocated and dispensed by appropriately trained persons. Detailed records of the amounts of the 
investigational product received, dispensed, and destroyed will be maintained. 
Unless otherwise notified, empty vials and vials with residual materials should be kept for 
inspection and accountability by the study monitor prior to their destruction or handled per local 
pharmacy standard operating procedures (SOPs) for clinical study drugs. To satisfy regulatory 
requirements regarding drug accountability, at the end of the study all remaining ALXN1210 
inventory will be reconciled and destroyed or returned to Alexion according to applicable 
regulations. 
Please refer to the ALXN1210 Pharmacy Manual for further information. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 46 of 86 
CONFIDENTIAL 
9.2. 
Treatments Administered 
Patients will receive ALXN1210 for 26 weeks during the Initial Evaluation Period. ALXN1210 
will be administered as an IV infusion over approximately 2 hours. ALXN1210 must NOT be 
administered as an IV push or bolus injection. 
The dose regimen for ALXN1210 during the Initial Evaluation Period is based on the patient’s 
last recorded study visit body weight (Table 6). Patients will receive a loading dose of 
ALXN1210 IV on Day 1, followed by maintenance dosing of ALXN1210 IV on Day 15 and 
q8w thereafter.  
Table 6: 
Loading and Maintenance Treatment Regimens 
Body Weighta 
Loading Dose (Day 1) 
Maintenance Dose (Days 15, 71, and 127) 
≥ 40 to < 60 kg 
2400 mg 
3000 mg 
≥ 60 to < 100 kg 
2700 mg 
3300 mg 
≥ 100 kg 
3000 mg 
3600 mg 
a Body weight as recorded at the last study visit. 
After the Initial Evaluation Period, all patients will roll over into an Extension Period (which will 
continue until the product is registered or approved [in accordance with country-specific 
regulations] or for up to 4.5 years, whichever occurs first) during which all patients will receive 
ALXN1210 q8w. 
The actual time of all dose administrations (including any retreatment/supplemental dose for 
retreatment [Section 8.3.2.1]) will be recorded in the patient’s eCRF. 
9.3. 
Method of Assignment to Treatment 
This is an open-label study. Patients who satisfy all criteria for enrollment will be assigned to 
study treatment with ALXN1210 at the Baseline Visit (Day 1). The interactive voice- or web-
response system (IxRS) will be used to assign vials containing ALXN1210 to each patient. 
9.4. 
Rationale for Selection of Doses in the Study 
The weight-based dosages of ALXN1210 in this study (Table 6) are premised on PK/PD data 
from early development studies in healthy adult volunteers as well as the available data from 
patients with PNH in an ongoing Phase 1b dose-finding study (ALXN1210-PNH-103) and an 
ongoing Phase 2 proof-of-concept study (ALXN1210-PNH-201). The selection of ALXN1210 
dose regimen for patients with aHUS is based on targeting immediate, complete and sustained 
inhibition of terminal complement in patients with PNH, which is expected to correspond to 
immediate, complete and sustained inhibition of terminal complement in patients with aHUS. 
9.5. 
Special Treatment Considerations 
Infusion of other monoclonal antibodies has been associated with infusion reactions, with onset 
typically during or shortly after completion of the infusion. Please refer to Appendix C for 
guidance on identifying and managing potential drug infusion reactions. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 47 of 86 
CONFIDENTIAL 
9.6. 
Prior and Concomitant Medications and Nonpharmacologic 
Procedures 
Prior medications (including vitamins and herbal preparations)—including those discussed in the 
exclusion criteria (Section 8.2) and procedures (any therapeutic intervention, such as 
surgery/biopsy or physical therapy) the patient takes or undergoes within 28 days prior to the 
start of Screening until the first dose of ALXN1210—will be recorded on the patient’s eCRF. In 
addition, history of meningococcal vaccination must be collected for the 3 years prior to first 
dose of study drug, and for patients < 18 years of age at the time of enrollment, vaccination 
history for Hib and Streptococcus pneumoniae must be collected from birth. 
All medication use and procedures undertaken during the study will be recorded in the patient’s 
source document/medical chart and eCRF. This record will include all prescription drugs, herbal 
products, vitamins, minerals, over-the-counter medications, and current medications. 
Concomitant medications will be recorded from the first infusion of study drug through 56 days 
after the patient’s last dose of study drug. Any changes in concomitant medications also will be 
recorded in the patient’s source document/medical chart and eCRF. Any concomitant medication 
deemed necessary for the patient’s standard of care during the study, or for the treatment of any 
AE, along with the allowed medications described below may be given at the discretion of the 
Investigator. However, it is the responsibility of the Investigator to ensure that details regarding 
all medications are recorded in full in the patient’s source document/medical chart and eCRF. 
9.7. 
Prohibited Medications and Procedures 
Patients are prohibited from receiving any of the following medications and procedures at any 
time after the first dose of study drug for all patients in the study (even those who discontinue 
ALXN1210 treatment but remain in study) until completion of the study or early termination of 
the patient from the study: 
• Eculizumab or other complement inhibitors 
• Use of any other investigational drug or device as part of a clinical trial. 
• IVIg (unless for an unrelated medical need e.g. hypogammaglobinemia)  
• Rituximab 
• PE/PI 
• New dialysis within the first 48-hour period following the first dose of ALXN1210 
unless there is a compelling medical need as assessed by (1) hypervolemia 
unresponsive to diuretics, (2) refractory electrolyte imbalance, or (3) new-onset 
uremic encephalopathy. Exceptions must be approved prior to administration of 
dialysis on a case-by-case basis by the Sponsor.   
The following concomitant medications and procedures are allowed under certain circumstances 
and with the following restrictions: 
• Use of other immunosuppressive therapies (such as steroids, mTORi [eg, sirolimus, 
everolimus], CNI [eg, cyclosporine or tacrolimus]) during the study are not allowed 
unless: a) part of an established post-transplant antirejection regime, or b) patient has 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 48 of 86 
CONFIDENTIAL 
confirmed anti-complement factor antibodies requiring immunosuppressive therapy, 
or c) steroids are being used for a condition other than aHUS (eg, asthma), or d) 
steroids initiated empirically prior to enrollment and are being tapered as standard of 
care.  
Any patients receiving other complement inhibitors (including eculizumab) or undergoing PE/PI 
after the first dose of study drug will be withdrawn from the study.  
9.8. 
Vaccination  
Due to its mechanism of action, the use of ALXN1210 increases the patient’s susceptibility to 
infection. To reduce the risk of infection, all patients must be vaccinated against N. meningitidis.  
Patients must be vaccinated against N. meningitidis within 3 years prior to, or at the time of, 
receiving the first dose of ALXN1210. Patients who will be treated with drug less than 2 weeks 
after receiving a meningococcal vaccine must receive treatment with appropriate prophylactic 
antibiotics until 2 weeks after vaccination. Vaccines against serotypes A, C, Y, W135, and B, 
where available, are recommended to prevent common pathogenic meningococcal serotypes. 
Patients must be vaccinated or revaccinated according to current national vaccination guidelines 
or local practice for vaccination use with complement inhibitors (eg, eculizumab). 
It is recognized that some patients who have not been vaccinated against N. meningitidis within 
3 years prior to receiving the first dose of ALXN1210 may not be able to receive a vaccination at 
the time of the first dose. Patients who have not been vaccinated prior to initiating ALXN1210 
treatment should receive prophylactic antibiotics prior to and for at least 2 weeks after 
meningococcal vaccination. 
Vaccination may not be sufficient to prevent meningococcal infection. Consideration should be 
given per official guidance and local practice on the appropriate use of antibacterial agents. All 
patients should be monitored for early signs of meningococcal infection, evaluated immediately 
if infection is suspected, and treated with appropriate antibiotics, if necessary. 
To increase risk awareness and promote quick disclosure of any potential signs or symptoms of 
infection experienced by the patients during the course of the study, patients will be provided a 
safety card to carry with them at all times and for 8 months after last dose of ALXN1210. 
Additional discussion and explanation of the potential risks, signs, and symptoms will occur at 
specific time points as part of the review of the patient safety card and throughout the study as 
described in the Schedule of Assessments (Table 1, Table 2, and Table 3).  
Patients < 18 years of age must also be vaccinated against Haemophilus influenzae type b (Hib) 
and Streptococcus pneumoniae according to national and local vaccination schedule guidelines, 
prior to, or at the time of, receiving the first dose of ALXN1210. 
Vaccination status for N. meningitidis, Hib, and S. pnemoniae will be recorded on the patient’s 
eCRF. 
9.9. 
Treatment Compliance 
Patients will be administered study drug in a controlled setting under the supervision of the 
Investigator or designee, thereby ensuring compliance with study drug administration. The 
Investigator or designee will ensure that all patients are adequately informed on the specific 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 49 of 86 
CONFIDENTIAL 
dosing regimen required for compliance with the study protocol, ensure that the patient receives 
the appropriate dose at the designated time points during the study and that adequate safety 
monitoring occurs during the infusion (Section 9.5). 
9.10. 
Contraception Guidance 
Before receiving study drug, female patients who consider themselves to be postmenopausal 
must provide evidence of menopause based on a combination of amenorrhea for at least 1 year 
and increased serum follicle-stimulating hormone (FSH) level (> 30 IU/L) (eg, in the absence of 
hormone replacement therapy, dietary phytoestrogens). 
Female patients of childbearing potential must use a highly effective or acceptable method of 
contraception (as defined below), starting at Screening and continuing for at least 8 months after 
the last dose of study drug. 
Highly effective contraceptive methods include: 
1. Hormonal contraception associated with inhibition of ovulation 
2. Intrauterine device 
3. Intrauterine hormone-releasing system 
4. Bilateral tubal occlusion 
5. Vasectomized partner, provided that the partner is the patient’s sole sexual partner 
6. Sexual abstinence, defined as refraining from heterosexual intercourse during the entire 
period of risk associated with the study drug treatment; reliability of sexual abstinence 
needs to be evaluated in relation to the duration of the clinical study and the preferred and 
usual lifestyle of the patient 
Acceptable contraceptive methods include: 
1. A combination of male condom with either cap, diaphragm, or sponge with spermicide 
(double barrier methods) 
The above-listed method(s) of contraception chosen for an individual patient can be determined 
by the Investigator with consideration for the patient’s medical history and concomitant 
medications. 
Male patients with a female spouse/partner of childbearing potential or a pregnant or 
breastfeeding spouse or partner must agree to use double barrier contraception (male condom 
plus appropriate barrier method for the female partner) while on treatment and for at least 8 
months after the last dose of study drug. Double barrier contraception is required even with 
documented medical assessment of surgical success of a vasectomy.  
Male patients must not donate sperm while on treatment and for at least 8 months after the last 
dose of study drug. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 50 of 86 
CONFIDENTIAL 
10. 
EFFICACY ASSESSMENTS 
10.1. 
Primary Efficacy Assessment 
The primary efficacy assessment is Complete TMA Response during the 26-week Initial 
Evaluation Period. The criteria for Complete TMA Response are the following:  
1. Normalization of platelet count 
2. Normalization of LDH 
3. ≥ 25% improvement in serum creatinine from baseline  
Patients must meet all Complete TMA Response criteria at 2 separate assessments obtained at 
least 4 weeks (28 days) apart, and any measurement in between, to be classified as having met 
the primary efficacy endpoint.  
10.2. 
Secondary Efficacy Assessments 
The following secondary efficacy assessments will be measured during the study:  
1. Dialysis requirement status 
2. Time to Complete TMA Response 
3. Complete TMA Response status over time 
4. Observed value and change from baseline in eGFR 
5. CKD stage, as evaluated by eGFR at select target days and classified as improved, stable 
(no change), or worsened compared to baseline 
6. Observed value and change from baseline in hematologic parameters (platelets, LDH, 
hemoglobin) 
7. Increase in hemoglobin of ≥ 20 g/L from baseline, observed at 2 separate assessments 
obtained at least 4 weeks (28 days) apart, and any measurement in between  
8. Change from baseline in QoL, as measured by EQ-5D-3L (all patients), FACIT Fatigue 
Version 4 (patients ≥ 18 years of age), and Pediatric FACIT Fatigue (patients < 18 years 
of age) questionnaires 
9. TMA parameters in patients who discontinue treatment but remain in the study 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 51 of 86 
CONFIDENTIAL 
11. 
SAFETY ASSESSMENTS 
The Investigator or his/her designee will meet with patients to discuss the potential safety risks 
of ALXN1210 and to give the Investigator the opportunity to address any of the patient’s safety 
concerns regarding the study. 
The collection of AEs will be monitored from the time informed consent is obtained until study 
completion. Investigators are instructed to follow any AEs through to their conclusion 
(resolution or stabilization) as described in Section 11.7.6. In the event of patient withdrawal 
from the study, AE monitoring should continue through the last patient’s last study visit if 
possible.  
The timing of the clinical and laboratory assessments to be performed is specified in the 
Schedule of Assessments (Table 1, Table 2, and Table 3). Any clinically significant abnormal 
results should be followed until resolution or stabilization. 
11.1. 
Demographic/Medical History 
11.1.1. 
Demographics and Baseline Characteristics  
A review of demographic parameters, including age, gender, race, and ethnicity will be 
performed. A complete medical history will be taken and documented. Weight and height will be 
recorded. Height will be measured at Screening only. 
11.1.2. 
Disease Characteristics 
The patient’s aHUS medical history, including onset of first aHUS symptom and date of 
diagnosis, will be documented at the Screening Visit.  
11.1.3. 
Medical History 
The patient’s medical history, including prior and concomitant conditions/disorders, will be 
recorded at the Screening Visit. Medication (prescription or over-the-counter, including vitamins 
and/or herbal supplements) use within 28 days prior to the start of Screening will also be 
recorded. Meningococcal vaccination within 3 years prior  to the first dose of study drug, and for 
patients < 18 years of age at the time of enrollment, vaccination history for Haemophilus 
influenzae type b (Hib) and Streptococcus pneumoniae from birth, will also be recorded, as 
described in Section 9.6. 
11.2. 
Physical Examinations 
A physical examination will include the following assessments: general appearance; skin; head, 
ear, eye, nose, and throat; neck; lymph nodes; chest; heart; abdominal cavity; limb; central 
nervous system; and musculoskeletal system. An abbreviated physical examination consists of a 
body system relevant examination based upon Investigator judgment and patient symptoms. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 52 of 86 
CONFIDENTIAL 
11.3. 
Vital Signs 
Vital sign measurements will be taken after the patient has been resting for at least 5 minutes, 
and will include systolic and diastolic BP (millimeters of mercury [mm Hg]), pulse oximetry, 
heart rate (beats/minute), respiratory rate (breaths/minute), and temperature (degrees Celsius [°C] 
or degrees Fahrenheit [°F]).  
11.4. 
Laboratory Assessments 
Samples for serum pregnancy, hematology, chemistry, coagulation, and urinalysis will be 
performed at the times specified in the Schedule of Assessments (Table 1, Table 2, and Table 3). 
Specific laboratory assessments are provided in Appendix D. Samples for laboratory assessments 
will be collected before each study drug administration. 
Evaluation of Inclusion Criteria 2a and 2b may be based on local laboratory results within 28 
days prior to the start of the Screening Period or laboratory results obtained during the Screening 
Period from a local or central laboratory. If a local laboratory is used to define eligibility, 
additional samples will be collected during the Screening Period for LDH, platelet count, 
hemoglobin and serum creatinine and tested at the central laboratory.  If patients are found to not 
meet the eligibility criteria for serum creatinine (Inclusion Criterion 2c) based on central 
laboratory results, they must not be enrolled into the study; if the subject has received the first 
dose of ALXN1210 the patient must be withdrawn from the study, and may be replaced. All 
analyses in this study will be based on results from the central laboratory. Laboratory results for 
Exclusion Criterion 1, Exclusion Criterion 2, and/or a central laboratory result for Inclusion 
Criterion 2c may not be available prior to first dose; results received after the first dose 
indicating that eligibility is not satisfied could lead to discontinuation and replacement of the 
patient. Please refer to the Laboratory Manual for time windows for collection and detailed 
instructions for collecting, processing, storing, and shipping blood samples for safety 
assessments. Laboratory reports will be made available to the Investigators in a timely manner 
for clinical management of patients.  
It is anticipated that some laboratory values may be outside the normal value range due to the 
underlying disease. The Investigators should use their medical judgment when assessing the 
clinical significance of these values. Clinical significance is defined as any variation in 
laboratory measurements that has medical relevance and which results in a change in medical 
care. If clinically significant laboratory changes from baseline value are noted, the changes will 
be documented as AEs on the AE eCRF. The Investigator will also assess the relationship to 
study treatment for all clinically significant out-of-range values (Section 15.9.3). The 
Investigator will continue to monitor the patient through additional laboratory assessments until 
(1) values have returned to the normal range or baseline level, or (2) in the judgment of the 
Investigator, values that are outside the normal range are not related to the administration of 
study drug or other protocol-specific procedures. 
11.4.1. 
Pregnancy Screen 
For females of childbearing potential, a serum or urine pregnancy test (ie, beta-human chorionic 
gonadotropin [β-hCG]) will be performed according to the Schedule of Assessments (Table 1, 
Table 2, and Table 3). 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 53 of 86 
CONFIDENTIAL 
11.4.2. 
Hematology 
Blood samples will be analyzed for the hematology parameters listed in Appendix D. 
11.4.3. 
Serum Chemistry 
Blood samples will be analyzed for the serum chemistry parameters listed in Appendix D. 
Indirect bilirubin is calculated from total and direct bilirubin values; therefore, indirect bilirubin 
results will not be available if direct bilirubin is below the limit of quantification. 
Serum FSH level will be measured during Screening for postmenopausal female patients to 
confirm their postmenopausal status. 
Chemistry assessments will be performed at the time points specified in the Schedule of 
Assessments (Table 1, Table 2, and Table 3). The eGFR will be calculated for all visits at which 
serum chemistries are collected using the Modification of Diet in Renal Disease formula in 
patients ≥18 years of age and Schwartz formula in patients < 18 years of age. 
11.4.4. 
Coagulation 
Blood samples will be analyzed for the coagulation parameters listed in Appendix D. 
11.4.5. 
Urinalysis and Urine Chemistry 
Urine samples will be analyzed for the parameters listed in Appendix D. A microscopic 
examination of urine samples will be performed if the results of the macroscopic analysis are 
abnormal. 
Urine samples will also be analyzed to measure proteins and creatinine in order to calculate the 
urine total protein:creatinine ratio. 
11.5. 
Electrocardiograms 
For each patient, single 12-lead digital ECGs will be collected according to the Schedule of 
Assessments (Table 1, Table 2, and Table 3). Patients must be supine for approximately 5 to 10 
minutes before ECG collection and remain supine but awake during ECG collection. 
The Investigator or designee will be responsible for reviewing the ECG to assess whether the 
ECG is within normal limits and to determine the clinical significance of the results. These 
assessments will be indicated on the CRF. For any clinically significant abnormal ECG results, 
the Investigator must contact the Medical Monitor to discuss the patient’s continued eligibility to 
participate in this protocol. 
11.6. 
Immunogenicity 
Blood samples will be collected to test for presence and titer of ADAs to ALXN1210 in serum 
prior to study drug administration as indicated in the Schedule of Assessments (Table 1, Table 2, 
and Table 3). Further characterization of antibody responses may be conducted as appropriate, 
including binding and neutralizing antibodies, PK/PD, safety, and activity of ALXN1210.  
Please refer to the Laboratory Manual for time windows for collection and detailed instructions 
for collecting, processing, storing, and shipping blood samples for immunogenicity analysis.  

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 54 of 86 
CONFIDENTIAL 
11.7. 
Adverse Event Management 
An AE is any untoward medical occurrence in a patient administered a pharmaceutical product 
and which does not necessarily have a causal relationship with this treatment. An AE can 
therefore be any unfavorable or unintended sign (eg, an abnormal laboratory finding), symptom, 
or disease temporally associated with the use of a medicinal product, whether or not considered 
related to the medicinal product. 
Situations in which an untoward medical occurrence did not occur (eg, hospitalization for 
elective surgery if planned before the start of the study, admissions for social reasons or 
convenience), and anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen are not AEs. 
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish drug effect. 
A medication error (including intentional misuse, abuse, and overdose of the product) or use 
other than what is defined in the protocol is not considered an AE unless there is an untoward 
medical occurrence as a result of a medication error.  
Cases of pregnancy that occur during maternal or paternal exposure to investigational product 
are to be reported within 24 hours of Investigator/site awareness. Data on fetal outcome and 
breastfeeding will be collected for regulatory reporting and safety evaluation. 
Adverse events should be recorded from the time of signed consent. An AE reported after 
informed consent but before study drug administration will be considered a pretreatment AE. 
Alexion has reporting standards for AEs that are to be followed as described in Section 11.7.6 
regardless of applicable regulatory requirements that may be less stringent.  
11.7.1. 
Targeted Adverse Events 
The following events are important identified risks in this study: 
• Meningococcal infections 
11.7.2. 
Severity Assessment 
The severity of AEs will be graded using Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.03 or higher. A grading (severity) scale is provided for each AE term. Each 
CTCAE term is a Lowest Level Term (LLT) per the Medical Dictionary for Regulatory 
Activities (MedDRA®). Each LLT will be coded to a MedDRA preferred term (PT). 
Grade refers to the severity of the AE. The CTCAE assigns a grade of 1 through 5, with unique 
clinical descriptions of severity for each AE (Table 7). 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 55 of 86 
CONFIDENTIAL 
Table 7: 
Adverse Event Severity Grading Scale 
Grade 
Description 
Grade 1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not 
indicated 
Grade 2 
Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental 
activities of daily living (ADL)a 
Grade 3 
Severe or medically significant, but not immediately life-threatening; hospitalization or prolongation 
of hospitalization indicated; disabling; limiting self-care ADLb 
Grade 4 
Life-threatening consequences; urgent intervention indicated. 
Grade 5 
Death related to AE. 
Abbreviations: ADL = activities of daily living; AE = adverse event 
a  Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing 
money, etc. 
b  Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and 
not bedridden. 
Any change in the severity of an AE should be documented based on specific guidelines in the 
eCRF Completion Guidelines. 
Severity and seriousness must be differentiated: severity describes the intensity of an AE, while 
the term seriousness refers to an AE that has met specific criteria for a SAE as described in 
Section 11.7.4. 
11.7.3. 
Causality Assessment 
An Investigator must provide a causality assessment (Unrelated, Unlikely, Possible, Probable, or 
Definite) for all AEs (both serious and nonserious) based upon the Investigator’s medical 
judgment and the observed symptoms associated with the event (Table 8). This assessment must 
be recorded on the eCRF and any additional forms as appropriate. 
Table 8: 
Causality Assessment Descriptions 
Assessment 
Description 
Not Related/Unrelated 
Suggests that there is no causal association between the investigational product 
and the reported event. 
Unlikely Related 
Suggests that the clinical picture is highly consistent with a cause other than the 
investigational product but attribution cannot be made with absolute certainty 
and a relationship between the investigational product and AE cannot be 
excluded with complete confidence. 
Possibly Related 
Suggests that treatment with the investigational product may have caused or 
contributed to the AE (ie, the event follows a reasonable temporal sequence 
from the time of drug administration and/or follows a known response pattern to 
the investigational product, but could also have been produced by other factors). 
Probably Related 
Suggests that a reasonable temporal sequence of the event with the 
investigational product administration exists and the likely causal association of 
the event with the investigational product. This will be based upon the known 
pharmacological action of the investigational product, known or previously 
reported adverse reactions to the investigational product or class of drugs, or 
judgment based on the Investigator’s clinical experience. 
Definitely Related 
Temporal relationship to the investigational product, other conditions 
(concurrent illness, concurrent medication reaction, or progression/expression 
of disease state) do not appear to explain event, corresponds with the known 
pharmaceutical profile, improvement on discontinuation, reappearance on 
rechallenge. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 56 of 86 
CONFIDENTIAL 
11.7.4. 
Serious Adverse Events 
An SAE is any untoward medical occurrence that: 
• Results in death 
• Is life-threatening (ie, patient was at risk of death at the time of the event) 
• Requires inpatient hospitalization or prolongation of existing hospitalization 
• Results in persistent or significant disability/incapacity 
• Is a congenital anomaly/birth defect 
Important medical events that may not result in death, be immediately life-threatening, or require 
hospitalization, may be considered a serious adverse event when, based upon appropriate 
medical judgment, they may jeopardize the patient or may require intervention to prevent one of 
the outcomes listed above. 
The expectedness of an SAE will be determined by Alexion, based on the current version of the 
IB. 
Information pertaining to the collection and reporting of SAEs is provided in Section 11.7.6.  
11.7.5. 
Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the IB and that the Investigator identifies as related to investigational product or procedure. 
United States Title 21 Code of Federal Regulations (CFR) 312.32 and European Union Clinical 
Trial Directive 2001/20/EC and the associated detailed guidances or national regulatory 
requirements in participating countries require the reporting of SUSARs. Alexion has procedures 
that will be followed for the recording and expedited reporting of SUSARs that are consistent 
with global regulations and the associated detailed guidances. Suspected unexpected serious 
adverse reactions will be reported to the national competent authority and IRBs/IECs where 
applicable. 
11.7.6. 
Collection and Reporting of Adverse Events 
11.7.6.1. All Adverse Events 
All AEs (serious and nonserious) will be collected from the signing of the informed consent form 
(ICF) until 8 weeks (56 days) after the last dose of study drug. For patients who discontinue 
study drug, but remain in the study, AE data collection will continue at subsequent visits per the 
Schedule of Assessments, until the patient's last visit. For patients who terminate early from the 
study, an ET visit will be conducted as soon as possible, and a follow-up phone call will be 
performed 8 weeks (± 5 days) following the patient’s last dose of the study drug. All AEs must 
be recorded on the eCRF upon the Investigator or his/her staff becoming aware of their 
occurrence. 
Investigators will be instructed to report the SAE including their assessment (eg, severity, 
seriousness, and potential relatedness to study drug) to Alexion Global Pharmacovigilance 
(GPV) within 24 hours of first awareness of the event via the Safety Gateway. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 57 of 86 
CONFIDENTIAL 
If a patient’s treatment is discontinued as a result of an AE, study site personnel must clearly 
capture the circumstances and data leading to any such dose interruption or discontinuation of 
treatment in the AE and Exposure pages of the eCRF. 
11.7.6.2. Serious Adverse Events 
All SAEs will be recorded regardless of the Investigator’s assessment of causality. No time limit 
exists on reporting SAEs that are thought to be causally related to the study drug. Investigators 
are at liberty to report SAEs irrespective of causality at any time.  
For all SAEs, the Investigator must provide the following: 
• Appropriate and requested follow-up information in the time frame detailed below 
• Causality of the SAE(s) 
• Treatment of/intervention for the SAE(s) 
• Outcome of the SAE(s) 
• Supporting medical records and laboratory/diagnostic information 
All SAEs must be reported to Alexion GPV within 24 hours of the Investigator or site staff 
awareness. These timelines for reporting SAE information to the sponsor need to be followed for 
the initial SAE report and for all follow-up SAE information.  
The Investigator or designee must record the SAE data in the eCRF and verify the accuracy of 
the information with corresponding source documents. The SAE report should be submitted 
electronically via the Safety Gateway.  
In the event that either the electronic data capture (EDC) or the Safety Gateway is unavailable at 
the site(s), the SAE must be reported on paper. Facsimile transmission or email may be used in 
the event of electronic submission failure. 
Email: 
 
Facsimile: 
 (NOTE: A local facsimile number will be provided for non-US 
sites) 
When further information becomes available, the eCRF should be updated with the new 
information and an updated SAE report should be submitted to Alexion GPV via Safety 
Gateway.  
If applicable, additional information such as relevant medical records should be submitted to 
Alexion GPV via the email address or fax number noted above. 
All paper forms and follow-up information submitted to the sponsor outside of the Safety 
Gateway (eg, discharge summary) should be kept in the appropriate section of the study file.  
11.7.7. 
Sponsor Reporting Requirements 
Alexion GPV or its legal representative is responsible for notifying the relevant regulatory 
authorities of SAEs meeting the reporting criteria. This protocol will use the current IB as the 
Reference Safety Document. The expectedness and reporting criteria of an SAE will be 
determined by the sponsor from the Reference Safety Document. 
PPD
PPD

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 58 of 86 
CONFIDENTIAL 
11.7.8. 
Investigator Reporting Requirements 
The Investigator must fulfill all local regulatory obligations required for the study Investigators. 
It is the PI’s responsibility to notify the IRB/IEC of all SAEs that occur at his or her site, as 
required per IRB/IEC SOPs. Investigators will also be notified of all SUSAR events that occur 
during the clinical study. Each site is responsible for notifying its IRB/IEC of these additional 
SAEs as per IRB/IEC SOPs.  
11.8. 
Exposure During Pregnancy and Breastfeeding 
Pregnancy data will be collected during this study for all patients and female spouse/partner of 
male patients. Exposure during pregnancy (also referred to as exposure in utero) can be the result 
of either maternal exposure or transmission of drug product via semen following paternal 
exposure. 
For all Alexion products, both in development or postapproval, exposure during pregnancy must 
be recorded and the pregnancy followed until the outcome of the pregnancy is known (ie, 
spontaneous miscarriage, elective termination, normal birth, or congenital abnormality), even if 
the patient discontinues study drug or withdraws from the study. 
If a female patient or a patient’s female partner becomes pregnant during the conduct of this 
study, the Investigator must submit the “Pregnancy Reporting and Outcome/Breastfeeding” form 
to Alexion GPV via fax or email (Section 11.7.6.2). When the outcome of the pregnancy 
becomes known, the form should be updated and submitted to Alexion GPV. If additional 
follow-up is required, the Investigator will be requested to provide the information. 
Exposure of an infant to an Alexion product during breastfeeding must also be reported (via the 
“Pregnancy Reporting and Outcome Form/Breastfeeding”) and any AEs experienced by the 
infant must be reported to Alexion Global Pharmacovigilance or designee via email or facsimile 
(Section 11.7.6). 
Pregnancy in itself is not regarded as an AE unless there is a suspicion that the investigational 
product may have interfered with the effectiveness of a contraceptive medication. However, 
complications of pregnancy and abnormal outcomes of pregnancy are AEs and may meet the 
criteria for an SAE (eg, ectopic pregnancy, spontaneous abortion, intrauterine fetal demise, 
neonatal death, or congenital anomaly). Elective abortions without complications should not be 
reported as AEs. 
11.9. 
Safety Monitoring 
The Alexion medical monitor, GPV physician, or both will monitor safety data throughout the 
course of the study. 
Alexion will review all information pertaining to the SAEs within the time frames mandated by 
company procedures. The Alexion medical monitor will, as appropriate, consult with the GPV 
safety physician, to review trends in safety data.  

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 59 of 86 
CONFIDENTIAL 
12. 
PHARMACOKINETICS AND PHARMACODYNAMICS 
ASSESSMENTS 
Blood samples for determination of serum drug concentrations and PD assessments will be 
collected before and after administration of study drug at the time points indicated in the 
Schedule of Assessments (Table 1, Table 2, and Table 3). The actual date and time (24-hour 
clock time) of each sampling will be recorded. The number of PK samples obtained for any 
given patient will not exceed the currently planned number of time points. 
End of infusion (EOI) blood samples for PK and PD assessment should be collected from the 
arm opposite to the arm used for infusing drug. Please refer to the Laboratory Study Manual for 
details on sample collection, including blood volume requirements.  
Assessments for PK/PD are as follows: 
1. Changes in serum ALXN1210 concentration over time  
2. Changes in free C5 concentrations 
3. Changes in free C5 and ALXN1210 concentration in patients who discontinue treatment 
but remain in the study 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 60 of 86 
CONFIDENTIAL 
13. 
EXPLORATORY ASSESSMENTS 
13.1. 
Biomarker and APC Activity Assessments 
Exploratory biomarker analyses will evaluate changes from baseline in biomarkers which may 
include, but are not limited to, markers of complement dysregulation (eg, Factor Ba), vascular 
inflammation (eg, sTNFR1), endothelial activation/damage (eg, sVCAM-1, thrombomodulin), 
coagulation (eg, D-dimer), and renal injury (eg, cystatin C). Additional analysis may include 
evaluation of ALXN1210 excretion in urine, cRBC hemolysis, total C5, autoantibodies to 
complement proteins (eg, anti-factor H) and APC activity (eg, Modified Ham’s test, complement 
deposition assays). 
Please refer to the Laboratory Study Manual for details on sample collection, including blood 
volume requirements. Biomarker samples may be analyzed after study completion.  
13.2. 
Genetics 
For patients who sign an additional optional consent, a whole blood sample for exploratory 
genetics can be drawn anytime during the study. Exploratory genetics may be performed to 
investigate genetic variants in genes known to be associated with aHUS, as well as to identify 
novel variants associated with aHUS, complement dysregulation, or metabolism or efficacy of 
ALXN1210. A patient (or legal guardian) may decline from providing a sample for exploratory 
genetics and still participate in the study. 
Please refer to the Laboratory Study Manual for details on sample collection, including blood 
volume requirements. 
13.3. 
Additional Signs or Symptoms of aHUS and Resource Utilization 
Resource utilization will be assessed using the Resource Utilization Patient Questionnaire 
(Appendix H) and additional signs or symptoms of aHUS will be assessed using the Patient-
reported aHUS Symptoms Questionnaire (Appendix I).  
The Investigator will evaluate extra-renal signs or symptoms of aHUS using a composite of 
clinical laboratory measurements (eg, troponin I, amylase, and lipase), vital signs (eg, heart rate, 
respiratory rate, pulse oximetry), and an organ system review. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 61 of 86 
CONFIDENTIAL 
14. 
DATA QUALITY ASSURANCE 
To ensure accurate, complete, and reliable data, the sponsor or its representatives will do the 
following: 
• Provide instructional material to the study sites, as appropriate. 
• Perform start-up training to instruct the Investigators and study personnel. This training 
will give instruction on the protocol, the completion of the eCRFs, and study procedures. 
• Make periodic visits to the study site. 
• Be available for consultation and stay in contact with the study site personnel by email, 
telephone, or facsimile. 
• Review and evaluate eCRF data and use standard computer edits to detect errors in data 
collection. 
• Conduct a quality review of the database. 
Authorized representatives of the sponsor, a regulatory authority, or an IRB/IEC may visit the 
site to perform audits or inspections, including source data verification. The purpose of an 
Alexion audit or inspection is to systematically and independently examine all study-related 
activities and documents to determine whether these activities were conducted, and data were 
recorded, analyzed, and accurately reported according to the protocol, good clinical practice 
(GCP) guidelines of the International Conference on Harmonisation (ICH), and any applicable 
regulatory requirements. The Investigator should contact the sponsor immediately if contacted by 
a regulatory agency about an inspection. 
To ensure the safety of participants in the study, and to ensure accurate, complete, and reliable 
data, the Investigator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study. If requested, the 
Investigator will provide the sponsor, applicable regulatory agencies, and applicable IRBs/IECs 
with direct access to original source documents. 
14.1. 
Data Collection and Storage 
All clinical data will be recorded promptly and accurately in the EDC system. When recorded 
electronically, CRFs will be electronically generated. All raw data will be preserved in order to 
maintain data integrity. The Investigator or designee will assume the responsibility of ensuring 
the completeness, accuracy, and timeliness of the clinical data. 
The EDC system is fully validated and compliant with CFR Title 21 Part 11. The EDC system 
will maintain a complete audit trail of all data changes. At each scheduled monitoring visit, the 
Investigator or designee will cooperate with the sponsor’s representative(s) for the periodic 
review of study documents to ensure the accuracy and completeness of the EDC system. 
Electronic consistency checks and manual review will be used to identify any errors or 
inconsistencies in the data. This information will be provided to the respective study sites by 
means of electronic or manual queries. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 62 of 86 
CONFIDENTIAL 
The Investigator or designee will prepare and maintain adequate and accurate source documents 
(medical records, ECGs, AE and concomitant medication reporting, raw data collection forms) 
designed to record all observations and other pertinent data for each patient receiving study drug. 
The Investigator will allow the sponsor’s representatives, contract designees, authorized 
regulatory authority inspectors, and the IRB/IEC to have direct access to all documents 
pertaining to the study. 
14.2. 
Records Retention 
The Investigator must maintain all documentation relating to the study for a period of 2 years 
after the last marketing application approval, or if not approved, 2 years following the 
discontinuance of the test article for investigation or longer if required per local regulations. If it 
becomes necessary for the sponsor or the sponsor’s designee or the Regulatory Authority to 
review any documentation relating to the study, the Investigator must permit access to such 
records. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 63 of 86 
CONFIDENTIAL 
15. 
STATISTICAL METHODS AND PLANNED ANALYSES 
15.1. 
General Considerations 
All data collected will be presented in summary tables and tabulations. All data, as well as any 
outcomes derived from the data, will be presented in detailed data listings. Graphical displays 
may also be provided, when appropriate. All analyses will be performed using SAS® release, 
version 9.4 or higher (SAS Institute Inc., Cary, NC, USA) or other validated statistical software. 
Continuous variables will be summarized using descriptive statistics, including number of 
observations and mean, standard deviation (SD), median, minimum, and maximum values. 
Categorical variables will be summarized by frequency counts and percentage of patients. Prior 
to finalizing and locking the database, all decisions concerning the inclusion or exclusion of data 
from the analysis for each patient will be determined by appropriate medical and statistical 
personnel. Any and all exclusions will be documented in patient listings.  
Details of the statistical analyses described below will be specified in a separate Statistical 
Analysis Plan (SAP) before database lock and analysis. Any change to the data analysis methods 
described in the protocol will require an amendment only if it changes the primary or key 
secondary objectives or the study conduct. Any other change to the data analysis methods 
described in the protocol or SAP, and the justification for making the change, will be described 
in the clinical study report (CSR). Additional exploratory analyses of the data may be conducted 
as deemed appropriate. 
An interim CSR will be prepared at the end of the 26-week Initial Evaluation Period, which will 
include efficacy, safety, and PK/PD analyses. A final CSR to summarize long-term efficacy, 
safety, and PK/PD will be produced at study completion. Available exploratory data will be 
summarized after study completion but may not be included in the CSR. 
For patients who discontinue ALXN1210 treatment, but remain in study, their data will be 
summarized along with data from patients remaining on treatment for 8 weeks (56 days) after 
their last dose of study drug. Data beyond this point will be presented in separate supplemental 
listings strictly limited to these patients. If such patients start retreatment with ALXN1210, their 
data from the time of study treatment restart will also be presented in separate supplemental 
listings limited to patients who will have restarted study treatment. However, data on AE, 
concomitant medications, and nonpharmacologic therapies and procedures from the time of 
treatment restart will be considered treatment emergent or concomitant, and will be summarized 
as such, combined with data from patients who remained on treatment throughout the study. 
Pharmacokinetic/PD and ADA data from patients who discontinue ALXN1210 treatment, but 
remain in study, will be summarized along with data from patients remaining on treatment, until 
8 weeks after their last dose of study drug. Data beyond this point will be presented in separate 
supplemental listings limited to these patients. If such patients start retreatment with ALXN1210, 
their PK/PD and ADA data from the time of study treatment restart will also be presented in 
separate supplemental listings limited to patients who will have restarted study treatment. 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 64 of 86 
CONFIDENTIAL 
15.2. 
Determination of Sample Size 
Approximately 55 patients will be enrolled in this study in order to yield at least 50 evaluable 
patients by Day 183. This sample size is deemed appropriate to provide complete safety 
information and the necessary precision level for the planned estimation. Assuming a proportion 
of Complete TMA response of 65%, 50 patients would yield a 95% confidence interval (CI) for 
the proportion of response with a half-width of approximately 15%. 
The sample size was increased to 55 patients to account for a potential 10% drop-out rate, thus 
yielding a total planned sample size of 55 patients. 
15.3. 
Analysis Sets 
Efficacy analyses will be performed on the FAS. The analysis of the FAS will be the primary 
analysis.  
The FAS will be based on a mITT approach where patients that were enrolled and treated based 
on verification of inclusion and exclusion criteria through local laboratory results and the 
assumption that all inclusion and exclusion criteria were satisfied will be excluded from the FAS 
if it is later shown that certain of the inclusion and exclusion criteria were in fact not satisfied 
once all Screening laboratory results are available. Based on the above, the FAS will include all 
patients who receive at least 1 dose of ALXN1210, have at least 1 postbaseline efficacy 
assessment, and meet all of the following criteria:  
• Patients who satisfy Inclusion Criterion number 2c  
• Patients who satisfy Exclusion Criterion number 1 
• Patients who satisfy Exclusion Criterion number 2 
The FAS will be determined prior to database lock and prior to the database snapshot for the 
analysis performed at the end of the 26-week Initial Evaluation Period. 
Safety analyses will be performed on the Safety Set, defined for all patients who receive at least 
1 dose of study drug.  
Pharmacokinetic and PD analyses will be performed on all patients who receive at least 1 dose of 
study drug and who have evaluable PK and PD data. 
15.4. 
Demographics and Baseline Characteristics 
Patient demographic and baseline characteristics, including medical history and transplant 
history, will be summarized for the FAS and Safety Set. 
15.5. 
Patient Disposition 
All patients will be included in the summaries of patient disposition, which will describe the 
frequency and percentage of patients enrolled and treated and who completed or withdrew from 
the study, along with reason for withdrawal from the study.  
The numbers of patients who are treated, discontinue treatment (along with reason for treatment 
discontinuation), complete or withdraw from the Initial Evaluation Period (along with reason for 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 65 of 86 
CONFIDENTIAL 
withdrawal), enter the Extension Period, and complete or withdraw from the Extension Period 
(along with reason for withdrawal) will be tabulated. 
15.6. 
Prior and Concomitant Medications and Nonpharmacologic 
Therapies and Procedures  
Each patient’s prior and concomitant medication use will be coded using the World Health 
Organization Drug Dictionary, and the frequency and percentage of concomitant medications 
will be summarized. Medications will be summarized by Anatomic-Therapeutic-Chemical 
(ATC) class and preferred drug name using frequency counts and percentages of patients in the 
Safety Set. 
15.7. 
Treatment Compliance 
The number of infusions received per patient will be tabulated for the FAS and Safety Set. 
15.8. 
Efficacy Analyses 
All efficacy analyses will be conducted for the FAS. The FAS is the primary analysis set for all 
efficacy analyses.  
15.8.1. 
Primary Efficacy Analysis 
The primary efficacy endpoint is Complete TMA Response during the 26-week Initial 
Evaluation Period. The primary analysis will consist in estimating the proportion of complete 
TMA responders among ALXN1210 treated patients. This will be performed by calculating the 
point estimate and a 95% CI for the proportion of complete TMA responders in ALXN1210 
treated patients. The CI will be based on the asymptotic Gaussian approximation method with a 
continuity correction. 
15.8.2. 
Key Secondary Efficacy Analyses 
15.8.2.1. Dialysis Requirement Status 
For patients requiring dialysis within 5 days prior to ALXN1210 treatment initiation, the 
proportion of patients no longer requiring dialysis will be summarized over time. A 2-sided 95% 
CI for the proportion receiving dialysis will be provided.   
15.8.2.2. Time to Complete TMA Response 
For the secondary efficacy endpoint of time to Complete TMA Response, Kaplan-Meier 
cumulative distribution curves will be generated along with 2-sided 95% CIs. The corresponding 
summary table will present the cumulative distribution function (CDF) estimate, the number of 
patients at risk, the number of patients responding, and the number of patients censored at each 
postbaseline time point. The table will also present first quartile, median, and third quartile, 
along with corresponding 2-sided 95% CI, of time to complete response. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 66 of 86 
CONFIDENTIAL 
15.8.2.3. Complete TMA Response Status Over Time 
Complete TMA Response will also be summarized over time by presenting the number and 
proportion of responders along with a 2-sided 95% CI for each postbaseline time point. 
15.8.2.4. eGFR Value and Change from Baseline 
Kidney function evaluated by eGFR will be summarized at baseline and each postbaseline time 
point using descriptive statistics for continuous variables for the observed value as well as the 
change from baseline. A value for eGFR will be imputed for patients requiring dialysis for acute 
kidney injury. A mixed model for repeated measures (MMRM) with the fixed, categorical effect 
of visit and fixed, continuous effect of the baseline value as covariates may be fit to test whether 
changes differ from zero at each time point.  
15.8.2.5. CKD Stage 
CKD stage (Appendix J) will be summarized over time by presenting the number and proportion 
of patients that improved (excluding those with Stage 1 at baseline as they cannot improve), 
worsened (excluding those with Stage 5 at baseline as they cannot worsen), and stayed the same 
compared to CKD stage at baseline. Stage 5 will be considered the worst category, while stage 1 
will be considered the best category. A 2-sided 95% CI for the proportion will be provided for 
each category.  
15.8.2.6. Hematologic Parameters 
Hematologic parameters (platelets, LDH, hemoglobin) will be summarized at baseline and each 
postbaseline time point using descriptive statistics for continuous variables for the observed 
value as well as the change from baseline. A MMRM with the fixed, categorical effect of visit 
and fixed, continuous effect of the specific test’s baseline value as covariates may be fit to test 
whether changes differ from zero at each time point. 
15.8.2.7. Hemoglobin Response 
The number and proportion of patients with an increase from baseline in hemoglobin ≥ 20g/L, 
observed at 2 separate assessments obtained at least 4 weeks (28 days) apart, and any 
measurement in between, will be summarized over time by presenting the number and proportion 
of responders along with a 2-sided 95% CI for each postbaseline time point. 
15.8.2.8. Quality of Life 
Quality of life will be evaluated using EQ-5D-3L (all patients; Appendix E), FACIT Fatigue 
version 4 Questionnaire (patients ≥ 18 years of age; Appendix F), and Pediatric FACIT Fatigue 
Questionnaire (patients < 18 years of age; Appendix G). The EQ-5D-3L and FACIT Fatigue data 
will be summarized at baseline and each postbaseline time point using descriptive statistics for 
continuous variables for the observed value as well as the change from baseline. A MMRM with 
the fixed, categorical effect of visit and fixed, continuous effect of the specific test’s baseline 
value as covariates may be fit to test whether changes differ from zero at each time point. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 67 of 86 
CONFIDENTIAL 
15.9. 
Safety Analyses 
All safety analyses will be performed for the Safety Set, defined for all patients who receive at 
least 1 dose of ALXN1210.  
15.9.1. 
Adverse Events 
The following definitions will be used for AEs: 
• Pretreatment adverse events: Any AE that starts after providing informed consent, but 
before the first infusion of study drug 
• Treatment-emergent adverse event: Any AE that starts during or after the first infusion of 
study drug. Adverse events that start 56 days or later after the last dose of study drug will 
not be considered as treatment emergent. 
• Treatment-emergent SAE: A treatment-emergent AE (TEAE) that is serious 
(Section 11.7.4 for definitions). 
The incidence of TEAEs, TEAEs leading to withdrawal from the study, TEAEs leading to study 
treatment discontinuation, drug-related TEAEs, TEAEs during study drug administration, severe 
TEAEs, and SAEs will be summarized. All AEs will be coded using MedDRA version 18 or 
higher, and will be summarized by system organ class (SOC) and PT overall, by severity, and by 
relationship to treatment. Detailed by-patient listings of TEAEs, SAEs, related TEAEs, TEAEs 
during study drug administration, TEAEs leading to withdrawal from the study, and TEAEs 
leading to study treatment discontinuation will be provided. 
15.9.2. 
Physical Examination and Vital Signs 
Adverse changes from baseline in physical examination findings will be classified as AEs and 
analyzed accordingly.  
Vital signs will be summarized descriptively at baseline and postbaseline time points and for 
changes from baseline. 
By-patient listings will be provided. 
15.9.3. 
Clinical Laboratory Tests 
Observed values and changes from baseline in clinical chemistry, hematology, and urinalysis 
will be summarized descriptively at baseline, and at each postbaseline time point. For laboratory 
results that can be classified as normal, low, or high based on normal range values, shifts from 
baseline in classification will be summarized for all study visits.  
15.9.4. 
Electrocardiograms 
By-patient data listings of ECG parameters will be provided. Electrocardiograms will be 
evaluated and summarized as normal, abnormal not clinically significant, or abnormal clinically 
significant. A shift from baseline to worst on-study ECG table will be presented for ECG results. 
Observed values and change from baseline in ECG intervals (PR, RR, QT, and QTc) will be 
summarized descriptively at baseline and each postbaseline time point. QT interval will be 
corrected for heart rate using Fridericia’s formula (QTcF).  

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 68 of 86 
CONFIDENTIAL 
15.9.5. 
Immunogenicity 
Abnormal immunogenicity findings, including the incidence and titers for ADAs to ALXN1210 
will be presented at each postbaseline time point in tabular format. The proportion of patients 
ever positive and the proportion of patients always negative may be explored. 
15.10. 
Pharmacokinetic/Pharmacodynamic Analyses 
Individual serum concentration data for all patients who receive at least 1 infusion of ALXN1210 
and who have evaluable PK data will be used to derive PK parameters for ALXN1210. 
Graphs of mean serum ALXN1210 concentration-time profiles will be constructed. Graphs of 
serum concentration-time profiles for individual patients may also be provided. Actual dose 
administration and sampling times will be used for all calculations. Descriptive statistics will be 
calculated for serum concentration data at each sampling time, as appropriate. Assessment of 
population-PK may be considered using data from this study or in combination with data from 
other studies. 
The PD effects of ALXN1210 administered IV will be evaluated by assessing the absolute values 
and changes and percentage changes from baseline in free C5 serum concentrations over time, as 
appropriate. Assessments of PK/PD relationships may be explored using data from this study or 
in combination with data from other studies.  
Pharmacodynamic analyses will be performed for all patients who receive at least 1 infusion of 
study drug and who have evaluable PD data. For PD parameters, summary tabulations of mean, 
SD, median, minimum, and maximum values will be presented for actual, change and percentage 
change from baseline. The relationship between changes in PD parameters, exploratory 
biomarkers, and the effects of treatment outcome may be evaluated. 
15.11. 
Exploratory Analyses 
15.11.1. 
Biomarker and APC Activity Analyses 
For exploratory biomarker analyses, summary statistics will be presented for actual, change and 
percentage change from baseline.  
The relationship between ALXN1210 concentration and exploratory biomarkers or the 
correlation between clinical benefit and key exploratory biomarkers may be assessed by 
graphical display. Exploratory analysis and potential relationships between clinical outcomes, 
PK/PD, genetic profile, and biomarker levels may also be performed. APC activity and 
autoantibody results will be summarized if evaluated.  
15.11.2. 
Genetics 
Exploratory genetics may be performed to investigate genetic variants in genes known to be 
associated with aHUS, as well as to identify novel genetic variants associated with aHUS, 
complement dysregulation, or metabolism or efficacy of ALXN1210.  

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 69 of 86 
CONFIDENTIAL 
15.11.3. 
Additional Signs or Symptoms of aHUS and Resource Utilization 
Resource utilization will be assessed using the Resource Utilization Patient Questionnaire 
(Appendix H) and additional signs or symptoms of aHUS will be assessed using the Patient-
reported aHUS Symptoms Questionnaire (Appendix I).  
Resource Utilization Questionnaire data and Patient-reported aHUS Symptoms Questionnaire 
data will be summarized at baseline and each postbaseline assessment using discrete data 
summary statistics. 
15.12. 
Other Statistical Issues 
15.12.1. 
Missing or Invalid Data 
If a Day 1 assessment is missing, the Screening assessment will be used as the baseline 
assessment.  
For evaluation of Complete TMA Response during the 26-week Initial Evaluation Period 
(primary endpoint), patients missing an efficacy assessment that is part of the definition of 
Complete TMA Response while still on-study, will have their last observation carried forward 
(LOCF). For patients who will have terminated early from the study prior to Week 26, their data 
up to the time of discontinuation will be used to assess Complete TMA Response.  
Missing data for QoL instruments will be handled as specified in the instructions for each 
instrument. 
15.13. 
Interim Analyses 
An interim analysis is planned for this study at the end of the 26-week Initial Evaluation Period 
after all patients have completed or withdrawn from the 26-week Initial Evaluation Period. 
Additionally, a second analysis to summarize long-term efficacy, safety, and PK parameters will 
be performed at the end of the 2-year Extension Period. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 70 of 86 
CONFIDENTIAL 
16. 
INFORMED CONSENT, ETHICAL REVIEW, AND 
REGULATORY CONSIDERATIONS 
16.1. 
Informed Consent and Assent 
The Investigator is responsible for ensuring that the patient understands the potential risks and 
benefits of participating in the study, including answering any questions the patient may have 
throughout the study and sharing in a timely manner any new information that may be relevant to 
the patient’s willingness to continue his or her participation in the study. 
The ICF will be used to explain the potential risks and benefits of study participation to the 
patient in simple terms before the patient is entered into the study, and to document that the 
patient is satisfied with his or her understanding of the risks and benefits of participating in the 
study and desires to participate in the study. 
The Investigator is responsible for ensuring that informed consent is given by each patient or the 
patient’s legal representative. This includes obtaining the appropriate signatures and dates on the 
ICF prior to the performance of any protocol procedures and prior to the administration of 
investigational product. The Investigator must retain the original version of the signed ICF. If the 
ICF is amended, the original signed, amended version must also be retained. A copy of the 
signed ICF(s) must be given to the patient. 
As used in this protocol, the term “informed consent” includes all informed consent given by 
patients or, as applicable, informed consent by their legally authorized representatives if the 
patient is unable to provide informed consent. 
16.2. 
Data Monitoring Committee 
An independent Data Monitoring Committee (DMC) comprising experts in relevant biomedical 
fields who have no direct relationship with the study will be appointed by the sponsor. The DMC 
will review and evaluate the accumulated study data for patient safety and make 
recommendations on continuing study drug administration or termination of the study. The DMC 
will review study information on a regular basis as outlined in the DMC charter, which is 
maintained separately from the study protocol.  
Final decisions regarding the conduct of the study will be made by the sponsor after consultation 
with the DMC. All appropriate regulatory authorities and Ethics Committees will be notified of 
any significant action.  
Each member of the DMC will be required to sign a contract agreement, which includes a 
confidentiality and financial disclosure statement, assuring no conflicts of interest as a condition 
for membership on the committee.  
The specific responsibilities of the DMC are described in the DMC Charter, which is maintained 
as a separate document. 
16.3. 
Ethical Review 
All ICFs must be compliant with the ICH guideline on GCPs.  

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 71 of 86 
CONFIDENTIAL 
Documentation of IRB/IEC approval of the protocol and the ICF must be provided to the sponsor 
before the study may begin at the investigational sites. The IRB/IEC(s) will review the protocol 
as required. 
16.4. 
Regulatory Considerations 
This study will be conducted in accordance with: 
1. Consensus ethics principles derived from international ethics guidelines, including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines 
2. The ICH GCP Guideline [E6] 
3. The ICH Clinical Trials of Medicinal Products in the Pediatric Population [E11] 
4. Applicable national and local laws and regulations 
The Investigator or designee will promptly submit the protocol to applicable IRB/IEC(s). 
Some of the obligations of the sponsor will be assigned to a third-party organization. 
An identification code assigned to each patient by the EDC system will be used in lieu of the 
patient’s name to protect the patient’s identity when reporting AEs and other study-related data. 
16.4.1. 
Changes/Deviations to Protocol 
The Investigator may need to deviate from the protocol to eliminate an immediate hazard to a 
trial subject without prior notification of the IRB/IEC. Any deviations from the protocol must be 
fully documented. The deviation and the reasons for it should be submitted to the IRB/IEC, 
Sponsor, and appropriate regulatory authority if required (ICH GCP E6 [R1] 4.5.4).  
After the commencement of the clinical trial, the Sponsor may make changes to the protocol. If 
those changes are significant, the regulatory authority and applicable IRB/IEC will be notified. 
16.5. 
Publication Policy 
The full terms regarding publication of the results of this study are outlined in the applicable 
Clinical Study Agreement. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 72 of 86 
CONFIDENTIAL 
17. 
LIST OF REFERENCES 
Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126:2459-65. 
Ceriotti F, Boyd JC, Klein G, Henny J, Queralto J, Kairisto V, et al. Reference intervals for 
serum creatinine concentrations: assessment of available data for global application. Clin Chem. 
2008;54:559-66. 
Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal 
allografts. Curr Opin Organ Transplant. 2014a;19:315-22. 
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin R, et al. Banff 2013 meeting report: 
inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. 
Am J Transplant. 2014b; 14:272–83. 
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney 
Disease. Kidney International Supplements. 2013; 3:19-62. 
Lee W, Bachman E, Aguzzi, R, Jang J-H, Kim J-S, Rottinghaus S, et al. ALXN1210, a long-
acting C5 inhibitor, results in rapid and sustained reduction of LDH with a monthly dosing 
interval in patients with PNH: preliminary data from a dose-escalation study. 2016; European 
Hematology Association Learning Center; 19 May 2016; cited 09 Jun 2016]. 
Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 
2011;6:60. 
Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic 
complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. 
Clin J Am Soc Nephrol. 2010;5:1844–59. 
Panteghini M. Enzymatic assays for creatinine: time for action. Clin Chem Lab Med. 
2008;46:567–72. 
Sellier-Leclerc A-L, Frémeaux-Bacchi V, Dragon-Durey M-A, Macher MA,  Niaudet P, Guest 
G, et al. et al. Differential impact of complement mutations on clinical characteristics in atypical 
hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400. 
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF, Bock SA, Branum A, et al. 
Second symposium on the definition and management of anaphylaxis: summary report--second 
National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network 
symposium. Ann Emerg Med. 2006;47(4):373-80. 
Sis B, Jhangri GS, Bunnag S, Allanach K, Kaplan B, Halloran. Endothelial Gene Expression in 
Kidney Transplants with Alloantibody Indicates Antibody-Mediated Damage Despite Lack of 
C4d Staining. Am J Transplant. 2009;9:2312-23. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 73 of 86 
CONFIDENTIAL 
18. 
APPENDICES 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 74 of 86 
CONFIDENTIAL 
APPENDIX A. COMMON CREATININE REFERENCE INTERVALS 
Age (Gender) Group 
97.5th Percentile Value (mg/dL) 
97.5th Percentile Value (μmol/L) 
11 to < 13 years of age  
0.71 
63 
13 to < 15 years of age 
0.81 
72 
15 to Adult (males) 
1.18 
104 
15 to Adult (females) 
1.02 
90 
Source: Adapted from Panteghini, 2008; Ceriotti, 2008. 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 75 of 86 
CONFIDENTIAL 
APPENDIX B. ANTIBODY MEDIATED REJECTION CRITERIA 
The revised (Banff 2013) classification of acute/active antibody-mediated rejection in renal 
allografts will be used to assess antibody mediated rejection. All 3 features must be present for 
diagnosis. 
Criteriaa,b,c 
Histologic evidence of acute tissue injury, including one or more of the following: 
Microvascular inflammation (g score > 0d and/or ptc score > 0) 
Intimal or transmural arteritis (v score > 0)e 
Acute thrombotic microangiopathy, in the absence of any other cause 
Acute tubular injury, in the absence of any other apparent cause 
Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the following: 
Linear C4d staining in peritubular capillaries (involving at least 10% of ptc by immunofluorescence on frozen 
sections, or any ptc by IHC on paraffin sections) 
At least moderate microvascular inflammation (sum of g and ptc scores ≥ 2)f 
Increased expression of gene transcripts in the biopsy tissue indicative of endothelial injury, if thoroughly 
validatedg 
Serologic evidence of donor-specific antibodies (HLA or other antigens) 
Source: Haas, 2014a 
a  For all antibody-mediated rejection (ABMR) diagnoses, it should be specified in the report whether the lesion is 
C4d-positive [involving ≥ 10% of ptc by immunofluorescence on frozen sections or any ptc by 
immunohistochemistry (IHC) on paraffin sections] or without evident C4d deposition (< 10% of ptc by 
immunofluorescence on frozen sections; completely negative by IHC on paraffin sections). 
b These lesions may be clinically acute, smoldering, or subclinical. Biopsies showing 2 of the 3 features, except 
those with donor specific antibody (DSA) and C4d without histologic abnormalities potentially related to AMR or 
cell-mediated rejection (the latter seen mainly in ABO-incompatible renal allografts) may be designated as 
‘suspicious’ for acute/active ABMR. 
c Modified from Haas, 2014b. 
d Recurrent/de-novo glomerulonephritis should be excluded. 
e It should be noted that these arterial lesions may be indicative of ABMR, T-cell-mediated rejection (TCMR), or 
mixed ABMR/TCMR. Arterial lesions are only scored in arteries having a continuous media with 2 or more 
smooth muscle layers. 
f In the presence of acute TCMR, borderline infiltrates, or evidence of infection, ptc score at least 2 alone is not 
sufficient to define moderate microvascular inflammation, and glomerulitis must be present (g score ≥ 1). 
g At present, the only validated molecular marker meeting this criterion is ENDAT expression, and this has only 
been validated in a single center (University of Alberta). The use of ENDAT expression at other centers or other 
test(s) of gene expression within the biopsy as evidence of ABMR must first undergo independent validation as 
was done for ENDAT expression by Sis, 2009. 
 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 76 of 86 
CONFIDENTIAL 
APPENDIX C. MANAGEMENT OF POTENTIAL DRUG INFUSION 
REACTIONS 
Infusion of other monoclonal antibodies has been associated with infusion reactions, with onset 
typically during or shortly after completion of the infusion. For this reason, patients will be 
carefully observed during each infusion.  
Patients who develop AEs of rash, hives, itching, or dysphagia of mild to moderate intensity 
during their infusion of ALXN1210 may continue to receive the infusion if deemed to be 
medically appropriate by the Investigator. Medical intervention may include, but is not limited 
to, slowing of the infusion rate (with or without treatment) or interrupting or stopping the 
infusion.  
Any acute reaction should be treated according to standard medical practice depending upon 
clinical signs and symptoms. If a patient requires medical intervention, the patient should remain 
at the investigational site until his or her condition stabilizes. The AE and any associated 
concomitant medications must be captured on the patient’s source document and eCRF.  
Some patients treated with IV infusions of monoclonal antibodies have experienced concurrent 
reactions with signs or symptoms that can be classified as acute allergic 
reactions/hypersensitivity reactions or cytokine release syndrome. Signs and symptoms include 
headache, fever, facial flushing, pruritus, myalgia, nausea, chest tightness, dyspnea, vomiting, 
erythema, abdominal discomfort, diaphoresis, shivers, hypertension, lightheadedness, 
hypotension, palpitations, and somnolence. Anaphylaxis might occur at any time during an 
infusion; therefore, patients will be monitored closely during the infusion. In addition, the re-
administration of some monoclonal antibodies has been associated with serum sickness-like 
reactions manifesting 1 to 14 days after drug administration. All AEs that may indicate an 
infusion-related response will be graded according to CTCAE Version4.03 or higher. 
Before any infusion is started, the treating physician and other appropriate personnel must make 
certain that medication (ie, adrenaline, inhaled beta agonists, antihistamines, corticosteroids) and 
other equipment to treat anaphylaxis are readily available. The infusion must be stopped 
immediately if Grade ≥ 2 allergic/hypersensitivity reactions (including drug fever) or Grade ≥ 3 
cytokine release syndrome/acute infusion reaction occurs. The sponsor must be notified within 
24 hours of any infusion reaction requiring interruption or discontinuation of study drug.  
Patients who experience a reaction during the administration of study drug should be treated 
according to institutional guidelines. For a Grade 1 or Grade 2 infusion reaction, the infusion 
should be temporarily stopped and treatment with an antihistamine (eg, diphenhydramine 25 to 
50 mg orally [PO] or equivalent) and acetaminophen (650 mg orally or equivalent) may be 
considered. If the patient’s signs and symptoms have resolved (with or without administration of 
the above medication), the infusion may be restarted. However, the patients should be infused at 
a slower rate and be monitored closely for any signs and symptoms of infusion reactions during 
the remainder of the infusion. Patients experiencing an infusion reaction should be observed in 
the clinic until resolution of the reaction, or until the Investigator determines the patient is no 
longer at risk. Patients who experience a severe reaction during administration of study drug 
resulting in discontinuation of study drug should undergo all scheduled safety, PK, and PD 
evaluations required by the protocol. 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 77 of 86 
CONFIDENTIAL 
If anaphylaxis occurs according to the criteria listed below, then administration of subcutaneous 
epinephrine (1/1000, 0.3 to 0.5 mL, or equivalent) should be considered. In the case of 
bronchospasm, treatment with an inhaled beta agonist also should be considered. Patients 
administered an antihistamine for the treatment or prevention of an infusion reaction should be 
given appropriate warnings about drowsiness and impairment of driving ability before being 
discharged from the center.  
Table 9: 
Clinical Criteria for Diagnosing Anaphylaxis 
Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled: 
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both 
(eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula), and at least 1 of the following: 
a. 
Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow 
(PEF), hypoxemia) 
b. Reduced blood pressure (BP) or associated symptoms of end-organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence) 
2. Two or more of the following that occur rapidly after exposure to a likely allergen for that patient (minutes 
to several hours): 
a. 
Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips/tongue/uvula) 
b. Respiratory compromise (eg, dyspnea, wheeze/bronchospasm, stridor, reduced PEF, hypoxemia) 
c. 
Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incontinence) 
d. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting) 
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours): 
a. 
Systolic BP of less than 90 mm Hg or greater than 30% decrease from that person’s baseline 
Source: Sampson, 2006 
Abbreviations: BP= blood pressure; PEF = peak expiratory flow 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 78 of 86 
CONFIDENTIAL 
APPENDIX D. PROTOCOL LABORATORY TESTS 
 
Hematology: 
Clinical Chemistry: 
Free hemoglobin 
Haptoglobin 
Hematocrit 
Hemoglobin 
Mean corpuscular hemoglobin 
Platelet count  
RBC distribution width 
RBC mean corpuscular volume 
RBC count  
Reticulocyte count 
White blood cell count  
White blood cell differential 
 
Coagulation Panel: 
International normalized ratio 
Prothrombin time 
Partial thromboplastin time 
 
Urine Chemistry: 
Microalbumin 
Creatinine 
Total protein 
 
Alanine aminotransferase 
Albumin 
Alkaline phosphatase 
Amylase 
Aspartate aminotransferase 
Bicarbonate 
Blood urea nitrogen 
C-reactive protein 
Calcium 
Chloride 
Creatinine 
Gamma-glutamyltransferase 
Glucose 
Lactate dehydrogenase 
Lipase 
Magnesium 
Phosphorus 
Potassium 
Sodium 
Total bilirubin (direct and indirect) 
Total protein 
Troponin I 
Uric acid 
 
 
Urinalysis: 
Albumin 
Appearance 
Bilirubin 
Blood 
Color 
Creatinine 
Glucose 
Ketone 
Nitrite 
pH 
Protein 
Specific gravity 
Urobilinogen 
 
Pregnancy and Menopausal Status Tests:
 
(females only) 
Beta human chorionic gonadotropin 
Serum follicle-stimulating hormone 
(postmenopausal only) 
 
Other: 
ADAMTS13 activity 
ADA 
Coombs, direct 
Free C5 
PK 
Shiga toxin-related HUS screen (eg, Shiga toxin 
enzyme immunoassay/PCR in stool/stool 
culture)  
 
Note: This table excludes exploratory tests 
Abbreviations: ADA = antidrug antibodies; ADAMTS13 = a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13; APC = alternative pathway of complement; C5 = complement 
component 5; HUS = hemolytic uremic syndrome; PCR = polymerase chain reaction; PK = pharmacokinetic; 
RBC = red blood cell 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 79 of 86 
CONFIDENTIAL 
APPENDIX E. EQ-5D-3L 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 80 of 86 
CONFIDENTIAL 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 81 of 86 
CONFIDENTIAL 
 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 82 of 86 
CONFIDENTIAL 
APPENDIX F. FACIT-FATIGUE 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 83 of 86 
CONFIDENTIAL 
APPENDIX G. PEDIATRIC FACIT-FATIGUE 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 84 of 86 
CONFIDENTIAL 
APPENDIX H. RESOURCE UTILIZATION PATIENT QUESTIONNAIRE 
 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 85 of 86 
CONFIDENTIAL 
APPENDIX I. PATIENT-REPORTED aHUS SYMPTOMS 
QUESTIONNAIRE 
 
 

Protocol ALXN1210-aHUS-311 
 
Alexion Pharmaceuticals, Inc. 
Amendment 4, 07 May 2019 
Page 86 of 86 
CONFIDENTIAL 
APPENDIX J. GLOMERULAR FILTRATION RATE 
CATEGORY/STAGE IN CHRONIC KIDNEY DISEASE 
GFR Category/Stage 
GFR (mL/min/1.73 m2) 
Terms 
G1 
≥ 90 
Normal or High 
G2 
60 - 89 
Mildly Decreaseda 
G3a 
45 - 59 
Mildly to Moderately Decreased 
G3b 
30 – 44 
Moderately to Severely Decreased 
G4 
15 – 29 
Severely Decreased 
G5 
< 15 
Kidney Failure 
a Relative to young adult level 
Note: In the absence of evidence of kidney damage, neither GFR category/stage G1 nor G2 fulfill the criteria for 
CKD 
Source: KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 
2013. 3: 19-62.